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GENETIC CODE EXPANSION IN BIOCHEMICAL INVESTIGATIONS AND 
BIOMEDICAL APPLICATIONS 
 
Nanxi Wang, Ph.D. 
University of Nebraska, 2017 
Advisor: Jiantao Guo 
Genetic code expansion provides a powerful tool for site-specific incorporation of unnatural 
amino acids (unAAs) with novel biochemical and physiological properties into proteins in live 
cells and organisms. To achieve this, a nonsense codon suppression system, which consists of an 
orthogonal aminoacyl-tRNA synthetase (aaRS) and tRNA pair that specifically decodes a 
nonsense codon (e.g., amber codon and quadruplet codon) with an unAA but do not “cross talk” 
with their endogenous counterparts, was established. This Ph.D. thesis presents our efforts on 
evolution and application of nonsense codon suppression systems for biochemical and biomedical 
investigations.  
In Chapter 1, a brief overview of genetic code expansion technique and recent advances in 
this area of research was given. To improve unAA incorporation efficiency, we focused on 
systematic evolution of two most commonly used orthogonal aaRS/tRNA pairs: PylRS/tRNAPyl 
and MjTyrRS/tRNATyr. We enhanced quadruplet codon decoding efficiency of PylRS/tRNAPyl 
pairs by completely randomizing the anticodon-stem loop of tRNAPyl (Chapter 3). In addition, we 
improved amber suppression efficiency of MjTyrRS/tRNATyr derivatives by engineering the 
anticodon binding pocket of MjTyrRS (Chapter 4). All these efforts lead to a further improvement 
in current nonsense codon suppression systems and may expand their applications in unAA 
mutagenesis. Next, we reported the application of an amber suppression system as an unnatural 
 
 
genetic switch to manipulate the expression of essential HIV-1 proteins, which resulted in either 
single-cycle or multicycle live-attenuated HIV-1 viruses (Chapter 2). These genetically modified 
viruses can be potentially used as preventive vaccines to protect against HIV-1 infection. Our 
methodology can also be applied to the generation of vaccines against other pathogens. 
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Genetic Code Expansion: An Overview and Recent Advances in Biochemical and 
Biomedical Research 
1.1 Introduction: an overview of genetic code expansion  
Genetic code expansion allows for site-specific incorporation of unnatural amino acids 
(unAAs), beyond the 20 canonical ones, into proteins in live cells and organisms. The major 
challenge for genetic code expansion is to introduce unAAs exclusively into proteins at pre-
determined sites. Since the first report demonstrating that an archaeal aminoacyl-tRNA synthetase 
(aaRS) and tRNA pair could be used to encode unAA in response to an amber nonsense codon in 
E. coli (Figure 1),1,2 this system has been widely adopted. Different sets of cross-species 
aaRS/tRNA pairs have been developed to adapt to a range of different expression hosts. Through 
directed evolutions and functional screenings,3,4 aaRS/tRNA pairs with altered amino acid 
specificity have been selected to direct the incorporation of novel unAAs into proteins in both 
prokaryotic and eukaryotic cells, and recently animals.5,6  
The ability to reprogram genetic code greatly expanded the scope of unAA mutagenesis for 
biochemical and biomedical research. Unlike traditional protein engineering strategies, genetic 
code expansion is not limited to the natural building blocks, but offers much broader structural 
diversity and functional versatility. Distinctive unAAs with unique biochemical and physiological 
properties have been installed in the target proteins using this system, such as spectroscopic 
probes,7,8 post-translational modifications,9,10 photo-crosslinkers,11 photocaged or chemically-
caged groups,12-14 metal chelators,15 and chemically reactive handles.16,17 Site-specific 
incorporation of these unAAs enables the observation and control of target proteins under 
physiological conditions in live cells or even in live animals. Further enrichment in protein 
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complexity can be achieved by selective chemical modifications at unAA-mutation sites for the 
study of more complicated cellular events. Genetically encoded unAAs have taken active roles in 
probing protein structure and functions, tracking protein localization, monitoring protein-protein 
interactions, and controlling enzymatic activities.6,18-20 More importantly, genetic code expansion 
has opened new frontiers for biomedical applications. For example, genetically encoded 
posttranslational modifications (PTMs) and mimics may enhance the immunogenicity of self-
proteins, which makes them promising candidates for therapeutic vaccines.21-23 The insertion of 
amber stop codons in viral genome provides a simple and effective strategy to develop preventive 
vaccines. 24-26  
To sum up, genetic code expansion has been proven particularly useful in expanding chemistry 
of living systems and turned into a key fundamental chemical biology tool. Herein, this chapter 
provides an overview of the genetic code expansion, and recent advances in the development and 
application of this technique.    
1.2 Orthogonal aaRS/tRNA pairs 
The key component of genetic code expansion is the orthogonal aaRS/tRNA pair (Figure 2). 
To apply the orthogonal aaRS/tRNA pair in live cells, several prerequisites needed to be fulfilled. 
First, no “cross-talk” should happen between this aaRS/tRNA pair and their counterparts in the 
host cells. To avoid misincorporation of canonical amino acids, it demands that the nonsense 
suppressor tRNA is only recognized by its cognate aaRS but not endogenous aaRSs. Second, the 
substrate specificity of aaRS should be altered towards a specific unAA while excluding all other 
canonical amino acids. Third, this orthogonal aaRS is required to charge the unAA onto its cognate 
tRNA but not onto any endogenous tRNA. In addition, the aminoacylated tRNA needs to be 
transported efficiently to a host ribosome or an engineered orthogonal ribosome, and positioned 
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correctly in response to either a nonsense triplet or a quadruplet codon to direct the incorporation 
of unAA into the nascent peptide. Last, the nonsense suppressor tRNA must outcompete the 
translation termination signal mediated by release factors in the host cells.  
To date, a tyrosyl-tRNA synthetase (TyrRS)/tRNATyr pair derived from Methanocaldococcus 
jannaschii and a pyrrolysyl-tRNA synthetase (PylRS)/pyrrolysyl-tRNA (tRNAPyl) pair derived 
from Methanosarcina mezei or Methanosarcina bakeri have emerged as the two major systems 
for genetic code expansion.6 MjTyrRS/tRNATyr variants are commonly used in E. coli. While 
PylRS/tRNAPyl variants are compatible with a much broader ranges of hosts, including both 
prokaryotes and eukaryotes.13,27-31 One noteworthy exception demonstrated that 
MjTyrRS/tRNATyr mutants could be functional in mammalian cells through the evolution of the 
orthogonality-determining elements.32 
To further expand the diversity of unAAs that could be incorporated into proteins in E. coli, 
orthogonal aaRS/tRNA pairs from other organisms have been developed, including a lysyl-tRNA 
synthetase/tRNALys pair33 and a glutamyl-tRNA synthetase/tRNAGlu pair34 derived from 
Pyrococcus horikoshii and a tryptophanyl-tRNA synthetase/tRNATrp pair35 from Saccharomyces 
cerevisiae. In yeast and mammalian cells, an E. coli tyrosyl-tRNA synthetase (EcTyrRS)/tRNATyr 
pair,36,37 an E. coli leucyl-tRNA synthetase (EcLeuRS)/tRNALeu pair, 38 and an E. coli 
tryptophanyl–tRNA synthetase (EcTrpRS)/tRNATrp pair39 have been utilized for unAA 
incorporation. In addition, the heterologous E. coli TyrRS (EcTyrRS)/Bacillus stearothermophiles 
tRNA (BstRNATyr) pair has been used as an efficient amber suppressor in mammalian cells40 and 




The first orthogonal MjTyrRS/tRNATyr pair that functioned properly in E. coli was reported 
in 2000.1 Although its orthogonality had yet to be optimized, this pair was used for the first in vivo 
amber suppression to incorporate p-methoxyphenylalanine.2 The initial evolution efforts were 
focused on enhancing the orthogonality and suppression efficiency of MjtRNATyr. Later, the 
research emphasis was shifted to engineer MjTyrRS to accommodate unAAs with novel functions 
and structures.  
The rapid expanded pool of MjTyrRS/tRNATyr variants allows for the site-specific 
incorporation of a large number of phenylalanine analogs with para-, meta-, or ortho-substitutions. 
For example, unAAs containing unsaturated carbon-carbon bonds, such as allyl,4 propargyl,41 
alkynyl42, and allenyl (unpublished data) groups have been incorporated into proteins. The 
incorporation of unAAs bearing chemically active handles, such as aryl halides,43 azide,44 ketone,45 
and boronic acid46 allowed for further modifications of unAA-containing proteins. Sulfated- or 
acetylated amino acids, such as sulfotyrosine (sTyr),47 and p-acetyl-L-phenylalanine (pAcF), have 
been used to generate homogenously modified proteins, which may enhance our understanding of 
PTMs.45 Alternative aromatic rings, such as naphthyl,43 hydroxyl- and methyl-coumarins48 have 
been used as protein probes to study protein structure and functions. Photo-caged tyrosine 
analogues, such as o-nitrobenzyl-tyrosine (ONBY)49 has been incorporated into proteins for light 
activation of enzymatic activity.  
1.2.2 PylRS/tRNAPyl 
In nature, pyrrolysyl-tRNA synthetase (PylRS) is responsible for charging the 22nd 
proteinogenic amino acid pyrrolysine (Pyl) onto pyrrolysyl-tRNA (tRNAPyl), a naturally occurring 
amber suppressor.50  
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The wild type PylRS possesses a deep and bulky hydrophobic pocket.51 The PylRS active site 
only forms two hydrogen bonds with Pyl in addition to the hydrophobic interactions. Due to the 
lack of specific interactions between Pyl and the binding pocket, PylRS displays a high tolerance 
toward variations in the side chains of its amino acid substrates, which enabled the evolution of 
PylRS with an expanded substrate flexibility for genetic code expansion.52 The wild-type and 
evolved PylRS/tRNAPyl pairs provide a versatile system for the genetic incorporation of a large 
variety of unAAs into bacteria, yeasts, mammalian cells, and animals with unique structural 
scaffolds and biochemical properties.28-30,53,54 In E. coli, more than 100 unAAs and several α-
hydroxy acids have been genetically encoded by employing the PylRS/tRNAPyl system.52  
According to the crystal structure of Desulfitobacterium hafniense PylRS (PDB ID: 2ZNI), 
the anticodon loop of tRNAPyl does not directly interact with PylRS and is not used as an identity 
element by PylRS.55 Thus, the PylRS/tRNAPyl system provides an additional advantage of a high 
tolerance towards changes in the tRNAPyl anticodon loop, allowing for the decoding of other non-
sense codons, such as UAA (ochre), UGA (opal), AGGA, AGUA, UAGA and CUAG. 30,54,56,57 In 
addition, the PylRS/tRNAPyl pair can be directly evolved in E. coli and transferred to eukaryotic 
cells for unnatural amino acid mutagenesis since it is both orthogonal in prokaryotic and eukaryotic 
cells.54 
1.2.3 EcTyrRS/BstRNATyr 
In mammalian cells, both the EcTyRS/EctRNATyr and the EcTyRS/BstRNATyr pairs have been 
used for amber suppression. However, BstRNATyr, harboring internal A- and B-box promoters, 
expressed more efficiently in mammalian cells than EctRNATyr.58 Therefore, EcTyrRS/BstRNATyr 
has been developed as a major system for the incorporation of unAAs into proteins in mammalian 
cells. A panel of functional groups, such as aryl halides, ketone, benzophenone, azide, and 
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propargyl have been genetically encoded by EcTyrRS/BstRNATyr pairs to facilitate the 
investigation of protein structure and function in mammalian cells.40,59,60 
1.3 Nonsense Codons 
Another important component of genetic code expansion is a unique codon to be assigned to 
encode an unAA. The standard genetic code, is well-conserved in nearly all organisms and uses 
61 codons to encode the 20 canonical amino acids. The remaining 3 codons (UAA, ochre; UGA, 
opal; and UAG, amber) are used as termination signals for the protein translation. Extensive effort 
has been made to tackle the challenges facing genetic code reprogramming by creating additional 
“nonsense” or “blank” codons, such as quadruplet codons and rare codons. 
1.3.1 Amber stop codon 
In E. coli, in-frame amber UAG codon occurs about 300 times in the genome, representing 
the least used stop codon (7%) compared to UAA and UGA codons.61 In mouse and human, the 
frequency of UAG codon usage elevates slightly but still remains the lowest among the three stop 
codons. Thus, the reassignment of UAG codon into a sense codon should pose minimum impact 
on the native proteome and is expected to be well-tolerated by the host cells.  
We and others have successfully incorporated unnatural amino acids in response to amber 
nonsense codons. To achieve this, one or more UAG codons were introduced in the coding gene 
of a protein of interest and a UAA or UGA codon was used as a “real” stop codon. To recognize 
the in-frame UAG codon, the anticodon of an orthogonal tRNA was mutated to CUA. Further 
evolution of the amber suppressor tRNA and cognate aaRS dramatically increased their amber 
suppression efficiency.3,4 Generally, the UAG codon should not be decoded by any cellular 
components in the absence of an aminoacylated (charged) amber suppressor tRNA. Instead, 
truncated proteins should be formed due to the presence of termination machinery in the host cells. 
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Only in the presence of a charged amber suppressor tRNA can a full-length protein be formed by 
read-through of the amber codon as a sense codon.  
To date, the UAG codon has been the most frequently used nonsense codon for unAA 
incorporation, while unAA mutagenesis at UAA or UGA codon has been minimally used.56,62 The 
UAG codon has also been used together with other nonsense codons30,31,62,63 to incorporate 
multiple unAAs into the same protein.  
1.3.2 Quadruplet codon 
The ability to incorporate multiple unAAs at defined positions in a single protein will provide 
a valuable tool to investigate protein structure, function, and dynamics. The number of unAAs that 
can be incorporated simultaneously is determined by the number of unique “blank” codons 
presented in a single gene. Since only two stop codons can currently be used, more “blank” codons 
are required to direct the incorporation of multiple unAAs. One solution is to redefine the meaning 
of naturally existing sense codons to create additional triplet nonsense codons, which will be 
discussed in the next section. An alternative solution is to employ unnatural quadruplet codons, 
which in theory provides 256 “blank” codons for unAA incorporation.  
The naturally occurring quadruplet codon decoding tRNA mutants normally contain an 
expanded anticodon loop.64 Transplanting such features into triplet decoding tRNAs rendered the 
generation of novel tRNAs capable of decoding quadruplet codons with unAAs. The Schultz group 
evolved a P. horikoshii lysyl tRNA synthetase/tRNALys pair for a less efficient insertion of L-
homoglutamine in response to an AGGA codon.33 An evolved MjTyrRS/tRNATyr pair was then 
used to incorporate p-acetyl-L-phenylalanine (pAcF) by suppressing UAGN codons in a 
genomically recoded bacteria strain.65 In addition to the above efforts, we showed for the first time 
that an evolved tRNAPyl variant could incorporate Nε-(tert-butyloxycarbonyl)-L-lysine (BocK) into 
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proteins in response to an AGGA codon in mammalian cells.54  We also conducted a systematic 
evolution and investigation of UAGN-decoding tRNAPyl variants in a genomically recoded 
bacteria strain.66 
Multi-site unAA incorporation has been achieved with the use of both amber codon and 
quadruplet codons. The Chin group developed an AGGA suppressor tRNA derived from M. 
jannaschii, which enables the incorporation of multiple p-azido-L-phenylalanine (pAzF) at specific 
sites in GST-MBP fusion protein.67 This newly evolved MjTyrRS/tRNATyr pair was shown to be 
mutually orthogonal to the MbPylRS/tRNAPyl pair in E. coli and enabled the expression of full 
length GST-CaM fusion protein containing both pAzF and N6-[(2-propynyloxy)carbonyl]-l-lysine 
(CAK) in response to AGGA and UAG codons, respectively.67 The incorporation of the above two 
unAAs enabled protein cyclization via a Cu(I)-catalysed Huisgen’s [2+3] cycloaddition reaction. 
In a separate work, the same group evolved AGGA, AGUA, UAGA and CUAG suppressor 
tRNAPyl variants.30 An azide and a norbornene were introduced into GST-CaM fusion protein by 
suppressing UAG and AGUA codons, which allowed for the protein to be selectively labeled with 
a FRET pair containing a strained alkyne and a tetrazine, respectively.30  
1.3.3 Rare codons 
An “amber-free” system utilizing sense codons (preferably rare codons) highlights the 
potential of an alternative approach for unAA incorporation. In nature, multiple redundant codons 
may encode a single amino acid. Theoretically, one codon is sufficient for coding each of the 
canonical 20 amino acids. Therefore, those rarely used sense codons offer a great potential to be 
redefined to new meanings without competing with release factors.68  
However, significant challenges needed to be overcome in order to achieve efficient sense 
codon reassignment. A major concern is the impact on the host proteome. Pioneering work by the 
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Church group showed that synonymous replacement of rare codons in the essential genes 
significantly impaired the fitness of the host cells for unknown reasons.69 In the same way, rare 
codon reassignment with unAAs may be unfavorable. Another concern is the competition with 
endogenous tRNAs at the codon of interest. This can be circumvented by engineering endogenous 
tRNAs to separate their assigned decoding pathways.70 Despite all of these challenges, recent 
progress has stimulated more attentions in this area of research. A rare sense codon, AGG, has 
been successfully redefined to encode different unAAs both in vitro and in vivo.63,70-72 In another 
example, the rare codon AUA has been made available for reassignment via deletion of the native 
tRNA and replacement with a tRNA from another species,73 but incorporation of unAAs using this 
system is still in development.  
1.4 Unnatural Amino Acids 
Unnatural amino acids play a crucial role in reprograming the genetic code. The genetic 
incorporation and application of novel unAAs in living cells will not only expand the repertoire of 
building blocks for protein synthesis, but also deepen our understanding of molecular basis of life.  
Similar to a canonical amino acid, an unAA contains an amine group, a carboxyl group, and 
a side chain that is specific to each amino acid. Theoretically, the side chain can be substituted 
with any desirable functional group, which provides potentially unlimited structural diversity and 
functional versatility. However, in a practical sense, only unAAs that possess proper physical, 
chemical, and biological properties can be genetically encoded. Appropriate solubility, stability, 
sizes, structures, and physicochemical properties are normally expected. In an attempt to mimic 
the natural substrates of MjTyrRS/tRNATyr and PylRS/tRNAPyl pairs, many unAAs maintain the 
core structure of phenylalanine or lysine. In general, these unAAs are larger than canonical amino 
acids due to complex side chains. 
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To date, more than 200 unAAs have been selectively introduced into proteins and this number 
is likely to grow rapidly.6 Site-specific incorporation of unAAs has enabled a broad range of 
applications in biochemical and biomedical research (Figure 3). The introduction of chemically 
reactive handles allows for site-selective labeling and modification of proteins, via bio-orthogonal 
reactions. A large number of bio-orthogonal reactions that can proceed selectively and efficiently 
under physiological conditions have been developed, such as Cu(I)-catalyzed or copper-free click 
reactions, the Staudinger ligation, and the inverse electron demand Diels-Alder reaction.5 Genetic 
encoding of these reactive handles into proteins allows for corresponding reactions to occur in 
living cells. Besides selective labeling, these unAAs are also particularly useful in generating bio-
conjugates and bio-materials with remarkable homogeneity and novel functions.74,75  
Genetic incorporation of unAAs containing spectroscopic probes provides a powerful tool for 
the analysis of protein structure and function. Spectroscopic probes may also provide useful 
information on protein dynamics, localization, protein-protein interactions, and other cellular 
processes. For example, isotope-labeled unAAs, such as 2-amino-3-(4-
(trifluoromethoxy)phenyl)propanoic acid (OCF3Phe), 
13C/15N-labeled p-methoxyphenylalanine 
(OMePhe), and 15N-labeled o-nitrobenzyl-tyrosine (ONBY) have been used to probe protein 
structure, dynamics and ligand binding using NMR.76 unAAs with specific infrared signatures, 
such as p-cyano-L-phenylalanine (pCNPhe)77 and p-azido-L-phenylalanine (pAzF)78 have been 
incorporated into proteins to probe protein dynamics and interactions. Site-directed spin-labeling 
has also been achieved with genetic incorporation of pAcF followed by chemical modification.79 
Direct incorporation of fluorescent unAAs provides a convenient tool to probe protein expression, 
localization and conformations in living cells.7,80    
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It has been known that PTMs play important roles in biological processes and cellular events. 
Some well-known PTMs include phosphorylation, sulfation, nitration, glycosylation, methylation, 
acetylation, and ubiquitination. However, it remains challenging to the biological role of PTMs 
due to the difficulty in the preparation and detection of PTM-proteins. The site-specific 
incorporation of unAAs containing proper PTMs or their mimics offers unprecedented control on 
the stoichiometry and homogeneity of the PTMs, allowing for the generation of homogenously 
modified proteins. Thus, these unAAs may facilitate the elucidation of the biological roles and 
functions of the PTMs.  
The site-specific incorporation of photo-caged unAAs provides precise temporal and spatial 
control on the structure and function of user-defined proteins. When introduced into proteins, the 
photo-caging group may temporarily block the molecular function of target proteins by either 
masking activity of essential amino acids or providing steric hindrance at or near the active site. 
After UV irradiation, the photo-caging group can be removed and the protein function can be 
restored. For example, photo-caged lysine, tyrosine, cysteine, selenocysteine, and serine have been 
genetically incorporated into proteins in various living cells, which enables a specific and rapid 
activation of protein function.49,81-85 
Photo-crosslinkers represent another group of photo-activatable reactive unAAs. The 
introduction of photo-crosslinkers enables the formation of covalent bonds between the unAA-
bearing proteins and its interacting partners under UV irradiation. Using this method, interactions 
that are weak, transient, or even unknown can be captured. For example, p-benzoyl-L-
phenylalanine (Bpa) has been proven particularly useful in mapping interactions between a target 
protein and its ligand or other macromolecules.11,86  
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1.5 Approaches to improve the efficiency of unAA incorporation 
To achieve optimal efficiency for unAA incorporation, extensive efforts have been devoted to 
evolving individual components of the translation machinery. Since genetic code expansion relies 
on an orthogonal aaRS/tRNA pair to direct the incorporation of unAA, systematic evolution 
approaches have been conducted to improve the inherent orthogonality of aaRS/tRNA pairs4,87,88 
and the catalytic activity of aaRS variants.27 The competition between amber suppressor tRNA 
and release factor 1 (RF1) was shown to be responsible for low unAA incorporation in response 
to amber nonsense codon. This has been successfully addressed with RF1 knock-out strains.31,89 
As genetic code expansion utilizes the host translational machinery, proper interactions between 
the aaRS/tRNA pair and cellular components is highly appreciated. Previous work highlighted the 
potential of improving unAA incorporation through maintaining optimal interactions between 
tRNA charged with unAA and EF-Tu.90,91 Also, the introduction of an orthogonal translation 
system which is only responsible for nonsense codon suppression provides advantageous options 
to enhance the incorporation efficiency.67,92,93 Adjusting other experimental details, such as the 
sequence context flanking the nonsense codons,94 the organization of expression vectors,95 and the 
gene delivery method96, may also contribute to an improved unAA incorporation system.  
1.5.1 Evolution of orthogonal aaRS/tRNA pairs 
A general in vivo selection method (Figure 4) to identify MjTyrRS/tRNATyr mutants with 
better incorporation efficiency has been established based on amber suppression of a toxic gene 
(negative selection) and an antibiotic-resistant reporter gene (positive selection).3 The negative 
selection was based on the suppression of amber mutations at permissive sites (Gln2 and Asp44) 
of barnase in the absence of unAA. The synthetases that could use any endogenous amino acids 
would produce functional barnase that would result in cell death. The positive selection was based 
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on the suppression of an amber mutation at a permissive site (Asp112) of chloramphenicol acetyl 
transferase-encoding gene (CAT or CmR) in the presence of unAA. Cells can only survive if the 
synthetase is able to incorporate unAA or natural amino acids. In order to obtain MjtRNATyr 
mutants with improved orthogonality, a MjtRNATyr library was generated and subjected to both 
positive and negative selections to identify functional and orthogonal MjtRNA mutants.3 The best 
candidate MjtRNATyr displayed a remarkable enhancement in the orthogonality and has been 
widely used.  
In order to alter the specificity of MjTyrRS towards different substrates, key residues in the 
amino acid binding pocket of MjTyrRS were randomized.2,4 The subsequent MjTyrRS library was 
subjected to both positive and negative selections to identify variants with the desired change in 
amino acid substrate specificity.4 By varying the stringency, order, and cycles of selections, the 
activity and fidelity of selected MjTyrRS can be adjusted to achieve an optimal incorporation 
efficiency. This selection scheme was proved generally applicable for the evolution of other 
aaRS/tRNA pairs, such as PylRS/tRNAPyl and EcTyrRS/tRNATyr.  
Positive-negative selections can be performed with different signal outputs by simply 
replacing the selection motifs. For example, a dual reporter combining T7-GFP and CAT gene was 
developed.4 Amber stop codons were placed in both the T7 RNA polymerase gene and the CAT 
gene. Amber suppression efficiency can then be determined by changes in the fluorescence 
intensity or by the concentration of chloramphenicol in the presence or absence of unAA.  
In another example, Taq polymerase and E. coli phenylalanyl-synthetase (EcPheRS) were 
used as a positive- and negative-selection reporter, respectively.88 The positive selection was 
performed in emulsified droplets. Functional tRNAs, which suppressed the amber stop codon, led 
to the generation of full-length Taq polymerases. The resulting tRNA mutants were amplified by 
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PCR with the Taq polymerase. In the negative selection, amber suppression with non-orthogonal 
tRNAs resulted in the generation of EcPheRS, which can utilize p-Cl-phenylalanine to cause cell 
death. By varying the concentration of p-Cl-phenylalanine and duration of negative selection, the 
selection stringency can be tuned.  
Since the conventional selection strategy requires multiple steps of plasmid extraction and re-
transformation, new strategies with fewer steps and faster speed are highly desirable. By 
integrating the target aaRS and the negative selection reporter tolC in the E. coli chromosome, and 
the positive selection reporter GFP on a separate plasmid, the whole selection process for 
identifying evolved aaRS candidates has been shortened to 1-2 days.97   
1.5.2 Release factor 1 knockout and an amber-free host to enhance amber suppression 
One major drawback of the amber suppression system is the low incorporation efficiency, due 
to the ambiguous functions of UAG codon as both a termination signal and an unAA-encoding 
codon. Although the amber suppressor tRNAs are generally efficient, they cannot completely 
outcompete the translation termination machinery. The resulting truncated protein products may 
interfere with the function of the target protein and can be deleterious to the host cells. In addition, 
extremely low efficiency of unAA insertions at multi-sites is usually observed due to competition 
with the termination signals. Furthermore, the suppression of genomic UAG codons of essential 
genes by exogenous amber suppressor tRNAs may have unpredictable consequences and cause 
destructive effects to the host cells.  
In prokaryotes, RF1 (release factor 1, recognizing UAA and UAG) and RF2 (release factor 2, 
recognizing UAA and UGA) signal the termination of translation by direct binding to the ribosome 
A site, which mediates the dissociation of the nascent peptide from the P site. To address the low 
amber suppression efficiency, initial efforts were focused on minimizing the RF1 mediated 
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translation termination. By decreasing the functional interaction between an orthogonal ribosome 
and RF1, the efficiency of amber suppression has been enhanced by more than 3 folds with a single 
amber codon and 20 folds with two amber codons.98 An RF1 knock-out in E. coli resulted in a 
dramatically enhanced amber suppression efficiency.89,99,100 Recent advances in genome editing 
allows for complete reassignment of UAG to a sense codon for protein translation. To achieve this, 
the Church group replaced all the instances of UAG with UAA in E. coli MG1655 followed by the 
removal of the RF1 encoding gene to generate C321.ΔA. This genomic recoded strain resulted in 
a tremendous enhancement in amber suppression efficiency.65,97 One noteworthy example using 
this strain resulted in the incorporation of up to 30 unAAs into a single protein with excellent yields 
(~50 mg/L) and fidelity (>95%).97 In addition, the C321.ΔA strain also works as an ideal 
expression host for quadruplet UAGN codon decoding. The Schultz group reported that the 
C321.ΔA strain enhanced the suppression efficiency of UAGN codon with a MjTyrRS/tRNATyr 
pair.65 Using the same strain, we performed a systematic evolution of UAGN suppressors and 
successfully identified several tRNAPyl mutants with robust quadruplet codon decoding efficiency 
for different unAAs.66 
1.5.3 Refining the interactions between the orthogonal tRNA and cellular components 
In prokaryotes, EF-Tu (elongation factor thermo unstable) recognizes and transfers the 
charged tRNA to the ribosome A site. Since the sequence of archaeal tRNA differs significantly 
from that of E. coli tRNA, a compromised compatibility of archaeal tRNA with the E. coli 
translational machinery may occur. Non-optimal interactions between EF-Tu and tRNA charged 
with unAA may result in low efficiency of protein synthesis.  
Two approaches have been taken to obtain optimal interactions between archaeal tRNA and 
EF-Tu in host cells. One approach utilizes evolved tRNAs to resolve such unfavorable interaction. 
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From tRNA libraries containing mutations at the binding interface with EF-Tu, Guo et al identified 
multiple MjtRNA mutants with significant enhanced amber suppression efficiency with a panel of 
distinct unAAs.90 Targeting the same sets of nucleotides, Maranhan et al successfully evolved 
tRNAs that specifically incorporate meta-halo-tyrosines.88 An alternative approach is to engineer 
a specific EF-Tu to facilitate the transfer of tRNA charged with unAAs. For example, Söll and co-
workers successfully incorporated o-phosphoserine (Sep) in response to amber stop codon using a 
Sep-specific aaRS/tRNA pair and an engineered EF-Tu (Sep-Tu).91 
1.5.4 Orthogonal ribosomes for enhancing nonsense codon suppression efficiency 
The natural ribosomes are less efficient at amber suppression or quadruplet codon decoding 
due to their natural function in synthesizing a triplet codon-based proteome. Conversely, the 
orthogonal ribosomes works in parallel, but independent of natural ribosomes; and are only 
responsible for translating the message from an orthogonal mRNA containing an orthogonal 
ribosome-binding site (RBS).92 In principle, more efficient site-direct incorporation of unAAs at 
amber stop codons and quadruplet codons can be achieved with evolved orthogonal ribosomes 
without affecting the synthesis of the native proteome.  
To generate an orthogonal ribosome, the Chin group created a 16S rRNA library containing 7 
randomized nucleotides in the 530 loop which is proximal to both tRNA and RF1 binding site.101 
Mutations that favored interactions with an amber suppressor tRNA over the translation 
termination were identified through a function screen. The resultant ribo-X showed significantly 
enhanced tRNA-dependent amber suppression with orthogonal mRNAs containing one or more 
amber stop codons. Using ribo-X as a starting point, 11 saturation mutagenesis libraries covering 
127 nucleotides in the tRNA binding site of ribosome were constructed in order to discover 
orthogonal ribosomes that acquire the ability to efficiently decode quadruplet codons while 
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maintaining amber suppression ability.67 Surprisingly, one resultant ribosome mutant, ribo-Q1, 
contained only two mutations (A1196G and A1197G), but the mutations drastically improved the 
decoding efficiency for a variety of quadruplet codons with tRNAs derived from M. jannaschii67 
or Methanosarcina species30. Using this O-ribosome, an insertion of multiple unAAs was achieved 
with two mutually orthogonal aaRS/tRNA pairs. 
1.6 Application of genetic code expansion in vaccine development 
Therapeutic and preventive vaccines, are important bio-products that help develop immunity 
against particular diseases. The scientific community has spent decades trying to develop 
therapeutic vaccines to cure various cancers. However, little progress has been made until now in 
the development of therapeutic vaccine partially due to the complexity of human immune system. 
Conversely, preventive vaccines have achieved great success in preventing a variety of diseases, 
such as polio, measles, and tetanus. However, key hurdles still exist that hinder developing 
efficient and safe vaccines for other diseases, such as AIDS.102  
Since previous efforts have not provided solutions for some irremediable diseases, novel 
vaccine strategies are urgently needed. Genetic code expansion has shown great potential in 
vaccine development. First, it offers a simple and effective method to increase immunogenicity of 
therapeutic vaccines. Second, it provides a useful tool for generating virus like-particles or 
conditionally-replicated live viruses that can be used as preventive vaccines.  
1.6.1 Design therapeutic vaccines using genetic code expansion 
The development of therapeutic vaccines against cancer or chronical degenerative diseases is 
a well-known challenge due to our natural tolerance against self-proteins. An autologous protein 
modified with an immunogenic unAA offers a simple and efficient strategy to circumvent self-
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tolerance. In one example, a murine tumor necrosis factor-α (mTNF-α) with a Tyr86pNO2F (p-
nitro-L-phenylalanine) mutation induced a high titer of antibody responses against both wild-type 
and pNO2F containing mTNF-α. Critically, it protected against lipopolysaccharide (LPS)-induced 
death in mice.21 High titers of antibody responses were also observed with mTNF-α containing 
pNO2F mutations at different locations.
22 Similar results were obtained with mTNF-α and EGF 
proteins containing different pNO2F, sTyr or 3-nitrotyrosine (3NO2Tyr) mutations, suggesting an 
important role for naturally occurring PTMs in antibody production.23  
1.6.2 Design preventive vaccines using genetic code expansion 
The applications of genetic code expansion in viral genome engineering have gained 
considerable interests. Site-specific incorporation of unAAs have been achieved with several 
human viral systems, including lentiviral vectors,103 Hepatitis-D,104 adeno-associated virus 2,105 
HIV-1,25,26,106 and Influenza-A.24 The further investigation of genetically modified viruses will 
provide valuable information regarding the host-pathogen interactions and related immune 
responses. Furthermore, the introduction of control elements, including nonsense codons and 
orthogonal aaRS/tRNA pairs, can be used to switch on or off the replication of live viruses. The 
resulting conditionally replicated viruses can be used as preventive vaccines to elicit robust 
immune responses without concerns of acquiring disease.    
We previously reported a general approach to generate live-attenuated HIV-1 virus, which can 
be potentially used as a preventive HIV vaccine.25 In this approach, one or multiple amber stop 
codons were installed in the essential genes in the HIV-1 genome and an evolved 
EcTyrRS/BstRNATyr pair was supplied exogenously. In the absence of an unAA, the amber stop 
codon cannot be decoded and the viral replication is switched off. In the presence of the unAA, 
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full-length viral protein can be expressed and the replication of HIV-1 can be switched on. To 
successfully apply this strategy in vivo, an important prerequisite is to elicit a robust immune 
response through sustained viral replication. We sought to solve this by integrating the control 
elements in the HIV-1 genome26 to enable the co-expression of the EcTyrRS/BstRNATyr pair and 
the HIV-1 viral proteins. The resultant virus strain obtains the ability of multicycle infection in T 
cells, which represents the first step towards a safe and effective HIV-1 live-attenuated vaccine.       
Using a similar approach, a live but replication-incompetent influenza A vaccine was 
generated and evaluated in animal models.24 In this approach, multiple amber stop codons were 
inserted in the viral genome to avoid reversion to wild-type during viral propagation. In 
conventional 293T cells or transgenic 293T cells stably expressing an evolved PylRS/tRNAPyl pair, 
the influenza virus was packaged in the presence of Nε-2-azidoethyloxycarbonyl-L-lysine. The 
virus was only observed to reproduce in the transgenic cells, suggesting a replication-incompetent 
feature. The in vivo tests demonstrated that the virus vaccine was safe in mice, ferrets, and guinea 
pigs. The virus vaccine elicited robust humoral, mucosal, and cell-mediated immunity in the tested 
animals, which was comparable to or stronger than the commercial inactivated or live-attenuated 
influenza vaccines. Potent protection was observed in animals charged with wild-type or 
antigenically distant viral strains. In addition, the virus vaccine was shown to inhibit the 
propagation of existing virus.  
1.7 Summary and remarks 
Genetic code expansion provides a versatile approach to generate unAA-modified proteins. 
Over the last decade, the repertoire of unAAs has rapidly expanded. A large variety of functional 
groups with distinctive structures have been selectively introduced into numerous target proteins 
in live cells. The site-specific incorporation of these unAAs relies on the suppression of nonsense 
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codons with orthogonal aaRS/tRNA pairs. High fidelity and good suppression efficiency have been 
achieved with aaRS/tRNA pairs derived from different species, allowing for unAA mutagenesis 
in all common protein expression hosts, including bacteria, yeasts, insect cells, and mammalian 
cells. Different approaches have been taken to improve the efficiency of unAA incorporation.  
Although the evolved aaRS/tRNA pairs have shown good orthogonality and suppression 
efficiency, a deeper understanding of the interaction between aaRS and tRNA is still highly 
desirable. To achieve this, we investigated two of the most commonly used orthogonal pairs: 
PylRS/tRNAPyl and MjTyrRS/tRNATyr. We improved quadruplet codon decoding efficiency 
through systematic evolution of PylRS/tRNAPyl pairs (Chapter 3). We enhanced amber 
suppression efficiency of evolved MjTyrRS/tRNATyr pairs by engineering the anticodon binding 
pocket of MjTyrRS (Chapter 4).  All of these efforts lead to a further improvement in orthogonal 
aaRS/tRNA pairs, which will likely expand the applications of unAA mutagenesis in biochemical 
and biomedical research.  
We and others have employed unAA mutagenesis for vaccine development.  As an example, 
developing a safe and effective HIV-1 vaccine may provide an ultimate solution for the worldwide 
pandemic. Since HIV-1 hijack host translational machinery for protein synthesis, a reprogramed 
protein translation system may be used to control viral replication. We reported the application of 
genetic code expansion in HIV-1 virus, resulting in either single-cycle or multicycle live-
attenuated HIV-1 viruses (Chapter 2). These genetically modified viruses may be used as 
preventive vaccines to protect against HIV-1 infection. Our strategy may be applied to the 








Figure 1. Reprogramming the genetic code. The unnatural amino acid (unAA) is specifically 
recognized by an orthogonal aminoacyl-tRNA synthetase (aaRS) and charged onto its cognate 
amber suppressor tRNA. The unAA is subsequently added into the growing polypeptide chain 







Figure 2. An orthogonal aaRS/tRNA pair for genetic code expansion. The orthogonal aaRS/tRNA 
pair should not “crosstalk” with the endogenous aaRS/tRNA pairs. The unAA should only be 
recognized by its orthogonal aaRS and charged onto the cognate tRNA, but not the endogenous 
tRNA. The orthogonal tRNA should not be recognized by endogenous tRNA to avoid 





Figure 3. Examples of unnatural amino acids. Based on functions, unAA can be classified into 
five major categories, including chemically reactive handles, posttranslational modifications or 






Figure 4. A general in vivo selection method for identifying evolved aaRS and tRNACUA variants. 
(A) In vivo screening of an aaRS library to identify aaRS variants with altered amino acid 







Development of Live-attenuated HIV-1 Viruses via Genetic Code Engineering 
Reproduced with permission from “Angewandte Chemie International Edition. 2014, 53, 4867.”, 
“ACS Synthetic Biology, in press. Unpublished work copyright 2017 American Chemical 
Society.”, and “Journal of chemical technology & biotechnology. 2017, 92, 455.” 
2.1 Introduction: A novel approach towards a HIV-1 live-attenuated vaccine  
 Since the first discovery of human immunodeficiency virus type 1 (HIV-1) in the last century, 
over 70 million people worldwide have been infected with HIV-1 and about half of them have died 
of this virus.107,108 In order to control the global HIV-1 pandemic, the development of a safe and 
effective vaccine is of critical importance. Unfortunately, after more than three decades of effort, 
an HIV-1 vaccine remains elusive. The development of an HIV-1 vaccine faces unprecedented 
scientific obstacles, such as the early establishment of latent viral reservoir,109 the enormous viral 
genetic diversities and mutation rates,110 the ability of the virus to escape from immune 
surveillance,111 and incapability of eliciting broadly neutralizing antibodies.112 To tackle these 
challenges, a deeper understanding of HIV-1 pathogenesis and immunology and novel approaches 
beyond the scope of traditional vaccinology are urgently needed. 
Among all the vaccine modalities developed and evaluated so far, a HIV-1 live attenuated 
vaccine (LAV) that was constructed by the deletion of nef gene (referred to as ∆nef-LAV hereafter) 
has conferred the best protective efficacy (95%) in a simian immunodeficiency virus (SIV)/rhesus 
macaque model.113-117 However, the SIV ∆nef-LAV retained pathogenic potentials and could lead 
to AIDS and even death in vaccinated neonatal and adult macaques,118-120 which was likely caused 
by uncontrolled viral replication. In addition, the ∆nef-LAV strains showed potentials to regain 
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virulence through long-term virus evolution.121-123 Therefore, HIV-1 LAV strategy has not been 
actively pursued in clinical trials.  
To solve the safety problems of conventional HIV-1 LAVs, we developed a novel approach 
to regulate the replication of HIV-1 with an unnatural genetic switch25,26,106  based on an amber 
suppression system. This genetic switch consists of (1) a unique amber suppressor tRNA, (2) an 
aaRS that specifically charges an unAA onto the amber suppressor tRNA, and (3) an unAA 
(Figure 5). The regulation of HIV-1 replication is achieved through the control of the biosynthesis 
of essential viral proteins. To this end, one or more amber mutations were inserted into essential 
genes of HIV-1. In the presence of the aaRS/tRNA pair and the unAA, full-length HIV-1 proteins 
can be synthesized and the replication of HIV-1 is thus turned on (on-state). In the absence of an 
unAA, only truncated viral proteins can be produced and the replication of HIV-1 is turned off 
(off-state). We have successfully demonstrated that the replication of HIV-1 can be turned on and 
off using this genetic switch in vitro by exogenously expressing the aaRS/tRNA pair. We also 
engineered all-in-one live-attenuated HIV-1 variants that contain a genomic copy of the amber 
suppression machinery. These strains gained the capability of multicycle replication and infection 
in mammalian cells. The use of an unAA-mediated genetic switch in vaccine design represents a 
completely novel approach towards the development of a safe and effective HIV-1 LAV. 
Potentially, this approach can be applied in the research and discovery of other live-attenuated or 
live but replication-incompetent vaccines.  
2.2 Approaches 
2.2.1 Single-cycle amber suppression-dependent HIV-1 variants  
We sought to control the replication of HIV-1 by our proposed unnatural genetic switch. In 
this work, one major challenge was to identify a suitable genetic switch with good suppression 
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efficiency and excellent fidelity on HIV-1 virus. We mainly focused on the EcTyrRS/BstRNATyr 
pair and its derivatives, including p-azido-L-phenylalanyl-tRNA synthetase (pAzFRS)/tRNATyr, p-
iodo-L-phenylalanyl-tRNA synthetase (pIodoFRS)/tRNATyr, and p-acetyl-L-phenylalanyl-tRNA 
synthetase (pAcFRS)/tRNATyr pairs.40 We also evaluated PylRS/tRNAPyl pairs, and specifically 
on o-nitrobenzyl-tyrosyl-tRNA synthetase (ONBY-RS)/tRNAPyl and o-nitrobenzyl-oxycarbonyl-
Nε-L-lysyl tRNA synthetase (ONBK-RS)/tRNAPyl pairs.49,124,125 First, we examined whether the 
pAzFRS/tRNATyr pair can be applied as a genetic switch in mammalian cells via a fluorescence 
based functional assay. Next, we investigated the incorporation of natural or unnatural amino acids 
into viral proteins with the aaRS/tRNA pairs mentioned above. At the meantime, we evaluated the 
effects of amber suppression on HIV-1 viability using p24-based infection assay by using TZM-
bl as host cell. Last, we successfully demonstrated that HIV-1 replication can be precisely 
controlled by proposed unnatural genetic switch strategy when pAzFRS/tRNATyr pair was 
employed.  
2.2.1.1 Detection of suppression efficiency and fidelity of the AzFRS/tRNATyr pair 
We first examined the suppression efficiency and fidelity of the pAzFRS/tRNATyr pair in 
mammalian cells. We co-transfected 293T cells with a plasmid pAzFRS that encodes the 
pAzFRS/tRNATyr pair and a plasmid pEGFP that encodes an enhanced green fluorescent protein 
(EGFP) with an in-frame amber mutation at position Tyr40. After transfection, 293T cells were 
incubated for an additional 12 h in DMEM media with or without 1 mM pAzF. As shown in Figure 
6, fluorescence signals were only detected in the presence of pAzF. While in the absence of pAzF, 
no detectable fluorescence signals were observed. In addition, tandem-mass spectrometry data 
(Figure 6C) confirmed that 4-aminophenylalanine (the reduction product of pAzF) was 
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incorporated at position 40 of EGFP exclusively. Taken together, the pAzFRS/tRNATyr pair 
showed an excellent suppression efficiency and fidelity in 293T cells.    
2.2.1.2 Screening of permissive sites in HIV-1 genome for amber mutations  
The HIV-1 genome is highly compact and harbors multiple overlapping regions.126  As shown 
in Figure 7,  the HIV-1 genome contains three major genes (gag, pol, and env) and six accessory 
genes (tat, rev, vif, vpu, vpr, and nef) flanked by 5’- and 3’-long terminal repeats (LTRs). The gag 
gene encodes viral structural proteins, including matrix protein p17 (MA), capsid protein p24 (CA), 
spacer peptide 1 (SP1), nucleocapsid protein (NC), spacer peptide 2 (SP2), and P6 protein. The 
pol gene encodes essential viral enzymes, including protease (PR), reverse transcriptase (RT), 
RNase H and integrase (IN). The env gene encodes glycoprotein gp120 or surface protein (SU) 
and gp41 or transmembrane protein (TM). The six accessory genes encode regulatory proteins (Tat 
and Rev) and auxiliary proteins (Vif, Vpu, Vpr and Nef). In addition, the primary HIV-1 transcript 
undergoes a sophisticated splicing process and can be processed to yield more than 40 different 
mRNA species.127 Thus, it is important to identify a suitable site for amber mutation or other 
genetic modifications. 
To screen for a proper mutation site, multiple HIV-1 variants were constructed (Table 1). A 
wild-type transmitter/founder HIV-1 virus pSUMA (catalog #11748, from Dr. John Kappes and 
Dr. Christina Ochsenbauer through NIH AIDS Reagent Program) was used as the parental 
template for subsequent cloning work. Amber mutations were inserted at gag, pol, and tat genes 
respectively by site-directed mutagenesis. The env gene was not included as a target gene due to a 
relatively higher mutation rate.  
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2.2.1.3 Genetic incorporation of tyrosine analogs into HIV-1 proteins 
When applying the unnatural genetic switch to control HIV-1 replication, the choice of unAA 
is of great importance. Ideally, unAAs should not interfere with the structure and function of viral 
proteins. Initially, we chose three close analogs of tyrosine, pAzF, pIodoF, and pAcF (1, 2, and 3 
in Figure 5C). In addition to having similar sizes to tyrosine, these unAAs contain chemically 
reactive handles that allow for selective modifications128-131 of viral proteins, which provide 
opportunities for remodeling the properties of vaccine strains in the future.    
We first evaluated the incorporation of pAzF into viral proteins. The pSUMA variants MA-
A119, MA-Y132, RT-F216, RT-F271, RT-L365, or Tat-T20 were co-transfected with pAzFRS 
into 293T cells. After 48 h of cultivation either in the presence or absence of pAzF, the resulting 
viruses were harvested and subjected to a p24 assay to quantify the viral titer. The presence and 
intensity of a blue color indicate the existence and the level of p24 being produced, respectively. 
As shown in Figure 8, in the presence of 1 mM pAzF, p24 expression was detected with all 
pSUMA variants although with different levels. In the absence of pAzF, p24 synthesis of MA-
Y132 and MA-A119 was undetectable. The harvested viruses were subsequently used to infect 
TZM-bl cells, an engineered cell line that express CD4 and CCR5 on its surface and being highly 
sensitive to infection with diverse isolates of HIV-1. TZM-bl cell also harbors a genomic copy of 
β-galactosidase gene under the control of HIV-1 promoter. Thus, HIV-1 infection can be detected 
with X-gal assay using this cell line. As shown in Figure 11G and 11H, extremely weak infection 
was observed with MA-A119 and RT-L365 variants. While no live virus was detected with other 
HIV-1 variants (Figure 11E and 11F).  
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Next, the incorporation of pIodoF and pAcF was examined by co-transfection 293T cells with 
a pSUMA variant (MA-A119, MA-Y132, CA-L268, RT-F216, RT-F271, RT-L365, or Tat-T20) 
and a plasmid pIodoFRS (encodes the pIodoFRS/tRNATyr pair) or a plasmid pAcFRS (encodes the 
pAcFRS/tRNATyr pair). As shown in Figure 9, p24 synthesis was almost undetectable with MA-
Y132, MA-A119, or Tat-T20 variants in the presence of pIodoF, suggesting that the incorporation 
of pIodoF in MA or Tat might disrupt the expression of p24. In contrast, strong p24 signals were 
obtained with these mutants in the presence of pAcF. However, the incorporation of pIodoF or 
pAcF did not lead to any infectious virus.  
2.2.1.4 Genetic incorporation of photocaged unAAs into HIV-1 proteins 
Genetically encoded photocaged unAAs can be used to regulate protein function and 
biological process with spatial and temporal precision in living cells.6 We envisaged that 
substitution of a natural amino acid with a photocaged unAA at protease cleavage sites in Gag may 
transiently block the cleavage process. After UV irradiation, the caged group can be removed and 
the cleavage site can be restored for proteolytic cleavage, which will result in generation of live 
viruses. We chose ONBY and ONBK (5 and 6 in Figure 5C) for the test. 
We first examined the incorporation of ONBY at MA/CA cleavage site using MA-Y132 
variant. After UV irradiation at 365nm, ONBY should be converted into tyrosine at position 132 
of matrix protein and result in a wild-type HIV-1 proteome. However, no infection activity was 
detected with MA-Y132ONBY before or after UV treatment. Next, we evaluated the incorporation 
of ONBK at CA/P2 cleavage site by using a HIV-1 variant CA-K359. After UV irradiation at 
365nm, ONBK should be de-caged and produce a lysine residue at position 359 of capsid protein. 
However, no infectious viruses were formed with or without UV treatment.  
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As a control, we examined the incorporation of ONBY and ONBK into EGFP in 293T cells. 
Green fluorescence was only detected in the presence of 0.4 mM ONBY (Figure 10A), suggesting 
efficient incorporation of ONBY. Genetically encoded ONBK in EGFP also led to a strong green 
fluorescence signal (Figure 10C), suggesting sufficient amber suppression efficiency. While in 
the absence of ONBY (Figure 10B) and ONBK (Figure 10D), no significant fluorescence signal 
was detected. These results suggest that the incorporation of ONBY or ONBK is not the limiting 
factor in our experimental design. Combining the above results, we reasoned that the failure in 
virus production was not due to low suppression efficiency but rather the disruption of protein 
functions by the encoded unAA. Since we have not fully explored available photocaged unAAs or 
screened sufficient amber mutation sites, we remain optimistic that optical-regulation of HIV-1 
replication can be achieved in the future.   
2.2.1.5 Genetic incorporation of tyrosine into HIV-1 proteins 
We sought to investigate whether the incorporation of unAAs caused the deficiency in virus 
production. As a comparison to unAA mutagenesis, we evaluated the effects of natural amino acid 
substitution on HIV-1 viability. We co-transfected MA-Y132 variant with a plasmid that encodes 
the TyrRS/tRNATyr pair into 293T cells. The incorporation of tyrosine at position 132 should result 
in wild-type Gag. Based on infection assays (Figure 11A), MA-Y132 showed near wild-type 
viability, suggesting that synonymous mutagenesis was tolerable at position 132 of Gag. In the 
control experiment, no infection was observed without the TyrRS/tRNATyr pair (Figure 11B). 
These results suggested that the incorporation of unAA at Y132 indeed interfered with the 
expression and/or function of Gag. Next, we tested the incorporation of tyrosine into MA-A119, 
CA-L268, RT-F216, RT-F271, RT-L365, and Tat-T20 variants respectively in the presence of the 
TyrRS/tRNATyr pair. Among all the HIV-1 variants being tested, only RT-F216 (Figure 11C) and 
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RT-L365 (Figure 11D) showed some infectivity, suggesting that natural amino acids substitution 
may also affect viral viability.  
2.2.1.6 Effects of suppression at genomic amber codons 
As the formation of virions was hardly observed in above experiments, we decided to assess 
potential impact of suppression at genomic amber codons. Since wild-type pSUMA (referred to as 
pSUMA-wt) has five amber stop codons, undesirable suppression at any of these positions may 
affect protein syntheses and following life cycle of the virus, which are crucial for HIV-1 infection. 
We co-transfected pSUMA-wt with plasmid pAzFRS into 293T cells. The viruses were harvested 
and subjected to p24 assay and infection assay to detect viral titer and viability. No obvious 
differences were observed in the presence or absence of the pAzFRS/tRNATyr pair (Figure 12). 
Therefore, amber suppression did not have an apparent negative effect on HIV-1 life cycles. 
Next, we constructed an HIV-1 variant based on pNL-GI, which harbors a genomic copy of 
hGFP and can directly indicate HIV-1 replication by fluorescence signals. An amber mutation was 
made at position 40 of hGFP to replace a tyrosine codon and the entire HIV-1 genome remained 
unchanged. The resulting HIV-1 variant pNL-GI-N40 was co-transfected with plasmid pAzFRS 
into 293T cells. We observed strong fluorescence with pNL-GI-N40 (Figure 13B) in the presence 
of AzF, which is comparable to the wild-type pNL-GI (Figure 13A), indicating a good suppression 
efficiency with the pAzFRS/tRNATyr pair. In addition, a near wild-type infection efficiency was 
observed with pNL-GI-N40TAG in the presence of pAzF (Figure 13D). Based on the above 
results, we concluded that amber suppression did not pose a significant pressure on viral proteome 
or viability.  
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2.2.1.7 To regulate the replication of HIV-1 using an unnatural genetic switch 
Since amber suppression with MA-Y132 and pNL-GI-N40 resulted in near wild-type 
infectivity, we decided to look for other suitable sites for unAA incorporation. We constructed a 
new HIV-1 variant, PR-Y59, which contains an amber mutation at position 59 of protease. Since 
Tyr59 is away from the catalytic center (PDB ID: 1EBZ),132 an unAA at this position might not 
cause a significant change in the structure and function of the protease. To test the efficiency of 
amber suppression, we first examined the incorporation of tyrosine at this position. As shown in 
Figure 14A, in the presence of the TyrRS/tRNATyr pair, the assembly of live viruses was observed 
with PR-Y59. To reduce the chance of HIV-1 to revert back to the virulent form, we installed two 
amber mutations at position 36 and 127 of matrix protein based on crystal structure (PDB 
ID:2H3F).133 It was shown clearly that the presence of the TyrRS/tRNATyr pair and MA-W36Q127 
variant led to infectious viruses (Figure 14C). In addition, we replaced Phe44 of matrix protein 
with tyrosine using the TyrRS/tRNATyr pair and obtained similar level of infection (Figure 14B).  
Next, we examined the amber suppression of PR-Y59 and MA-W36Q127 with the 
pAzFRS/tRNATyr pair. Encouragingly, only in the presence of 1 mM pAzF, PR-Y59 and MA-
W36Q127 showed infection activity (Figure 15). As a control, no live viruses were generated with 
PR-Y59 or MA-W36Q127 in the absence of pAzF.  Since the infected cells do not contain the 
genetic switch (pAzFRS/tRNATyr pair and pAzF), the infection lasts for only one-cycle and no 
progeny viruses will be produced, which partially addresses the safety concerns on HIV-1 LAVs. 
Then we tested the stringency of the unnatural genetic switch by comparing the tissue culture 
infectious dose 50 (TCID50) values in the presence (on-state) or the absence (off-state) of pAzF 
(Figure 15). The TCID50 of PR-Y59 was 0.00 at off-state in comparison to 1.31×10
3 at on-state, 




observed with MA-W36Q127 at on-state, while no infection activity (0.00) was observed at off-
state, which also confirms the tight control on the viral replication by our unnatural genetic switch.   
In summary, we have demonstrated that a stringent control of HIV-1 replication can be 
achieved by using an unnatural genetic switch in vitro. The ability to incorporate different 
functional groups with E. coli and archaeal aaRS/tRNA pairs allows for further modifications of 
viral proteins, which can be potentially used to improve the safety and efficacy of our vaccine 
strains. 
2.2.2 Multi-cycle amber suppression-dependent HIV-1 variants 
In previous sections, we have demonstrated a precise control of the replication of HIV-1 by 
an unnatural genetic switch. Since the host cells do not have the unique amber suppressor 
aaRS/tRNA pair, these variants cannot complete a second round of replication or infection. 
Therefore, these single-cycle HIV-1 LAV strains should be safe but may not be effective to induce 
desirable immune responses in the vaccination host due to a short window of infection. To 
overcome this potential drawback, HIV-1 variants that are able to undergo multiple cycles of 
replication and remain under a stringent control are needed.     
To achieve this goal, we constructed all-in-one live-attenuated HIV-1 variants by sequentially 
inserting all control elements of the unnatural genetic switch into HIV-1 genome (pNL4-3 strain). 
First, we screened genomic sites that allow for the insertion of a large piece of foreign DNA. Next, 
we inserted a genomic copy of aaRS between env and nef of pNL4-3 genome and examined the 
infectivity of the resulting pNL43-aaRS mutants. Then, we inserted a DNA cassette containing 
tRNATyr under the control of human U6 promoter into pNL43-AzFRS at different locus and 
orientations to afford four pNL43-AzFRS-tRNA variants. After evaluation of both viral infectivity 
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and proper function of the inserted pAzFRS/tRNATyr pair, we chose the best candidate pNL43-
AzFRS-tRNA-2 for subsequent experiments. pNL43-Trp36-AzFRS-tRNA-2 and pNL43-Tyr59-
AzFRS-tRNA-2 were constructed by inserting amber mutation into HIV-1 matrix protein and 
protease respectively. The infectivity and multicycle replication of the above two strains were 
examined. We demonstrated that the unnatural genetic switch could be used to turn on and off the 
replication of multicycle HIV-1 variants.  
2.2.2.1 Screening of genomic insertion sites for aaRS/tRNA pairs 
HIV-1 genome is highly compact and contains many overlapping regions. The insertion of a 
large piece of foreign DNA may interfere with HIV-1 genome, proteome and even normal life 
cycle. Therefore, it is critical to identify a proper insertion site for the aaRS/tRNA pair. Previously, 
GFP-encoding gene (~720bp) has been successfully inserted into HIV-1 genome at two different 
positions. In HIV-1-iGFP, gfp gene is inserted between MA and CA.134  In HIV-1-NL-GI or pNL-
GI, gfp gene is inserted at the 5’-end of nef gene.135 We compared the effects of genomic insertion 
sites by evaluating the infectivity of these two HIV-1 variants using TZM-bl cell based infection 
assay. As shown in Figure 16, both HIV-1-iGFP and HIV-1-NL-GI showed strong infections, and 
HIV-1-NL-GI exhibited relatively higher infectivity. In addition, the study of Δnef-HIV vaccine 
showed that the deletion in the nef gene and surrounding regions is tolerable. Thus, we decided to 
insert encoding genes of the aaRS/tRNA pair into nef region. 
2.2.2.2 Construction and evaluation of HIV-aaRS variants 
To investigate the genomic insertion of aaRS/tRNA encoding gene at the nef region, we chose 
pNL4-3 (catalog #114, from Dr. Malcolm Martin through NIH AIDS Reagent Program) which 
encodes a full-length HIV-1 genome as the parental template for subsequent cloning. We focused 
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on E. coli based pAzFRS/tRNATyr pair, which has successfully worked as a genetic switch for 
regulating single-cycle HIV-1 variants. pNL43-AzFRS was constructed by inserting pAzFRS-
encoding gene (1284 bp, 52% GC content) at the intergenic region between env and nef gene. As 
a control, EGFP-encoding gene (720 bp, 62% GC content) was inserted at the same position to 
afford pNL43-EGFP. Each of the above two constructs was transfected into 293 T cells and the 
viruses were used to infect TZM-bl cells. As shown in Figure 17, both pNL43-AzFRS and pNL43-
EGFP resulted in the assembly of infectious viruses, albeit with lower titers comparing to the wild-
type pNL4-3 (pNL43-wt). To further validate the genetic plasticity at nef region, we constructed 
pNL43-BocKRS by inserting BocKRS-encoding gene (1260 bp, 43% GC content) at the same 
position. Similar to ONBY-RS and ONBK-RS, BocKRS was derived from PylRS. The 
BocKRS/tRNAPyl pair specifically recognizes Nε-(tert-butoxycarbonyl)-L-lysine (BocK) and can 
be potentially used as another class of unnatural genetic switch for the generation of HIV-1 LAVs. 
As shown in Figure 17, pNL43-BocKRS also led to a moderate infectivity, which was relatively 
lower than that of pNL43-wt. Again, it confirms that the intergenic region between env and nef 
gene is a proper locus for the insertion of foreign DNA with varying length and GC contents.  
2.2.2.3 Construction and evaluation of HIV-AzFRS-tRNA variants 
Next, we inserted another essential control element of the genetic switch, the amber suppressor 
tRNA, into HIV-1 genome. A human RNA polymerase III U6 promoter was used to drive the 
transcription of prokaryotic tRNATyr. Four new constructs were generated by inserting the U6-
tRNATyr cassette (351bp, 30% GC content) at different loci with different orientations. First, the 
U6-tRNATyr cassette was inserted between AzFRS and nef, in the same (pNL43-AzFRS-tRNA-1) 
or the opposite (pNL43-AzFRS-tRNA-2) direction of AzFRS transcription. Then, the tRNA 
transcription cassette was inserted between env and AzFRS, in the same (pNL43-AzFRS-tRNA-3) 
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or the opposite (pNL43-AzFRS-tRNA-4) direction of AzFRS transcription. These constructs were 
designed to cover all possible combinations of AzFRS and U6-tRNATyr cassettes at the env/nef 
locus. By examining these constructs (Figure 18A), we also evaluated the potential polar effects 
resulting from transcription and translation of neighboring genes. We performed TZM-bl-based 
infection assay to assess the infectivity of these constructs. As shown in Figure 18B, the insertion 
of U6-tRNATyr between AzFRS/nef led to strong infectivity in both pNL43-AzFRS-tRNA-1 and 
pNL43-AzFRS-tRNA-2. While the insertion at env/AzFRS only led to pNL43-AzFRS-tRNA-4 
that displayed similar level of infectivity.  
Next, we examined whether the inserted AzFRS and U6-tRNATyr cassettes can function 
properly as a genetic switch in mammalian cells. To achieve this, we devised a fluorescence-based 
functional assay by co-transfecting each of these four constructs with a plasmid pEGFP into 293T 
cells. Since pEGFP has an in-frame amber mutation, only when the pAzFRS-tRNATyr pair was 
transcribed and processed correctly, they could decode the amber mutation and lead to 
fluorescence signal in the presence of pAzF. As shown in Figure 18C, the inserted 
pAzFRS/tRNATyr pair was functional in all four constructs.  
2.2.2.4 Construction and evaluation of multicycle HIV-UAG-AzFRS-tRNA variants.  
Since pNL43-AzFRS-tRNA-2 gave the best infectivity and amber suppression efficiency, we 
decided to use it for subsequent cloning. Based on pNL43-AzFRS-tRNA-2, we generated two new 
constructs by installing amber stop codon at either position 36 of matrix protein (pNL-Trp36-
AzFRS-tRNA-2) or at position 59 of protease (pNL-Tyr59-AzFRS-tRNA-2).  
First, we examined the infection activity of these two constructs by TZM-bl cell-based 
infection assay and TCID50 measurement. As shown in Figure 19A, both of the pNL-Trp36-
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AzFRS-tRNA-2 and pNL-Tyr59-AzFRS-tRNA-2 variants led to infectious viruses in the presence 
of pAzF, while no live viruses were generated in the absence of pAzF. According to the TCID50 
values (Figure 19B), the infectivity of both constructs was significantly attenuated compared to 
that of the wild-type pNL4-3. However, the number of viral particles formed by these two 
constructs were close to that of wild-type viruses (Figure 19B). The discrepancy between total 
number of viral particles and the number of virions (infectious viral particles) produced by pNL-
Trp36-AzFRS-tRNA-2 and pNL-Tyr59-AzFRS-tRNA-2 indicated that the amber suppression did 
not significantly affect the function of HIV-1 genome, however, it might interfere with the 
generation of infectious viruses at the translational level.  
Next, we examined the multicycle replication of pNL-Trp36-AzFRS-tRNA-2 and pNL-
Tyr59-AzFRS-tRNA-2 variants. These two constructs were transfected into 293T cells in the 
presence of 1 mM pAzF. 48 h post transfection, viruses were harvested and used to infect SupT1 
cells that express high level of CD4 on the surface and can support multicycle replication of HIV-
1. One day post infection, SupT1 cells were washed twice to remove any free virus particles in the 
culture media.  Then the infected SupT1 cells were cultivated in the presence or absence of 1 mM 
pAzF. As shown in Table 2, multicycle replication of pNL43-Trp36-AzFRS-tRNA-2 and pNL43-
Tyr59-AzFRS-tRNA-2 were achieved. According to TCID50 measurements, mild but continuous 
replication was observed with both constructs in SupT1 cells after two weeks’ cultivation in the 
presence of pAzF. pNL43-Tyr59-AzFRS-tRNA-2 displayed better infectivity than pNL43-Trp36-
AzFRS-tRNA-2. In the control experiment, no live viruses were generated after two weeks’ 
cultivation in the absence of pAzF, suggesting a good stringency of the unnatural genetic switch. 
Comparing with the parental wild-type pNL4-3 viruses, infectivity of both constructs was 
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significantly lower. In addition, pNL4-3 showed slightly lower titer in the presence of pAzF than 
in the absence of pAzF.  
We examined HIV-1 viral RNA (vRNA) and viral DNA (vDNA) in SupT1 cells that were 
infected with pNL43-Trp36-AzFRS-tRNA-2 and pNL43-Tyr59-AzFRS-tRNA-2 using 
RNAscope in situ hybridization and DNAscope ISH. Viral transcription was observed both in the 
presence and absence of pAzF. In the presence of pAzF, significant higher level of viral 
transcription was observed in both constructs. In addition, the transcription level of pNL43-Trp36-
AzFRS-tRNA-2 was slightly lower than that of pNL43-Tyr59-AzFRS-tRNA-2, which is 
consistent with the infectivity measurements. As a negative control, no transcription was detected 
in the uninfected SupT1 cells. As a positive control, robust transcription signals were detected in 
ACH2 cells with PMA stimulation. Based on DNAscope ISH, integration of pNL43-Trp36-
AzFRS-tRNA-2 and pNL43-Tyr59-AzFRS-tRNA-2 DNA was observed in infected SupT1 cells 
in the presence of absence of pAzF.  
2.2.3 Attempts to improve the replication capacity of amber suppression-dependent HIV-1 
variants  
2.2.3.1 Construction and examination of an amber-codon-free HIV-1 variant 
The wild-type pNL4-3 uses five amber stop codons to terminate protein translation. When 
applying the unnatural genetic switch in HIV-1, the amber suppressor tRNA may outcompete 
release factors and lead to read-through at these amber stop codons, which may cause negative 
effects on HIV-1 protein synthesis, virus assembly, and infectivity. Therefore, we decided to 
construct an amber-codon-free HIV-1 variant. To achieve this, we first replaced the amber stop 
codon (UAG) of HIV-1 vif, vpu, vpr, and rev genes with ochre stop codon (UAA) respectively to 
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afford pNL43-vif-UAA, pNL43-vpu-UAA, pNL43-vpr-UAA, and pNL43-rev-UAA. As shown in 
Figure 21, the infectivity of these four mutants was similar to that of wild-type pNL4-3 virus. 
Next, we generated an amber-codon-free pNL4-3 mutant, pNL43-all-UAA, by replacing all five 
UAG codons with UAA codons. According to the infection assay, pNL43-all-UAA retains a 
similar level of infection activity as the parental pNL4-3 virus, suggesting that amber stop codons 
were nonessential in HIV-1 virus. By preventing undesired amber suppression, the amber-free 
construct provides a useful tool for HIV-1 LAV research.    
2.2.3.2 Attempts to increase transcription level of the aaRS/tRNA pair 
As shown in Figure 6 and Figure 18, the intensity of fluorescence signal was significantly 
weakened after transferring the encoding genes of pAzFRS/tRNATyr pair onto HIV-1 genome, 
which suggested a reduction in its amber suppression activity. Since the inherent enzymatic 
activity of pAzFRS remains unchanged, we reasoned that the reduction might result from position 
effect of the pAzFRS-U6-tRNATyr cassette.  
To confirm our hypothesis, we measured the transcription level of pAzFRS. As shown in 
Figure 22A, the levels of pAzFRS mRNA transcribed from pNL43-Trp36-AzFRS-tRNA-2 and 
pNL43-Tyr59-AzFRs-tRNA-2 were significantly lower than that from a separate plasmid pAzFRS. 
To increase the transcription level of pAzFRS in HIV-1 genome, we introduced a strong CMV 
promoter in the front of AzFRS gene to generate pNL43-Trp36-CMV-AzFRS-tRNA-2 and pNL43-
Tyr59-CMV-AzFRS-tRNA-2 mutant. However, no improvement in infectivity was observed with 
these mutants Figure 22B. While when the pAzFRS/tRNATyr pair was supplied on a separate 
plasmid, the infectivity was significantly improved (Figure 22B), indicating that the transcription 
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level of the pAzFRS/tRNATyr pair may be one of the limiting factors for the low replication 
capacity of amber-suppression dependent HIV-1 variants.  
Several research groups have demonstrated that the use of multiple tRNA transcription 
cassettes could increase the amber suppression efficiency in mammalian cells.136,137 Using pNL43-
AzFRS-tRNA-2 as a parental plasmid, two constructs pNL43-AzFRS-2tRNA-F and pNL43-
AzFRS-2tRNA-R were generated by inserting an additional U6-tRNATyr cassette between env and 
AzFRS gene at the same or opposition direction of AzFRS gene. We evaluated whether 
transcription from the novel tRNATyr-pAzFRS-tRNATyr cassette was beneficial for amber 
suppression. Based on fluorescence assay, the inserted cassette was functional (Figure 23). But 
unfortunately, no live virus was generated, suggesting that the insertion of the second tRNA 
transcription cassette may have interfered with the expression or function of viral proteins. 
2.2.3.3 Supplement of viral proteins   
We reasoned that the insertion of amber stop codon and foreign DNA in essential genes of 
HIV-1 may interfere the expression of downstream viral proteins. To test our hypothesis, we 
replenished each viral protein from a separate plasmid to assist viral production. We co-transfected 
pNL43-Tyr59-AzFRS-tRNA-2 variant with a plasmid138-144 that over-expresses one of the nine 
HIV-1 proteins, namely Gag, Env, Pol, Nef, Tat, Vif, Vpr, Rev, or Vphu into 293T cells. Since 
over-expression of protease is toxic to the cells, only integrate and reverse transcriptase were 
included in the Pol supplement experiment. 48 h after transfection, the viruses were harvested and 
used to infect TZM-bl cells. As shown in Figure 24, there was no significant difference between 
each testing group. One plausible explanation is that the amber suppression in the protease did not 
affect the expression or function of other viral proteins but posed negative effects on protease itself.  
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2.2.3.4 Effect of unAA concentration on amber suppression 
Generally, 1 mM unAA is employed for amber suppression both in vitro and in vivo, albeit 
higher concentration (up to 10 mM) of unAA was also well tolerated.12,136,137 We attempted to 
reduce the working concentration of unAA for amber suppression. Firstly, a low concentration of 
unAA may reduce potential long-term toxicity of our vaccine strains. Secondly, it will be more 
economically feasible for future investigations on animal models. To achieve this, we determined 
amber suppression with different concentrations of pAzF in 293T cells. As shown in Figure 25, 
lower concentration of pAzF, such as 0.1 mM, led to efficient amber suppression. There was no 
significant difference in the expression levels of GFP between 0.1 and 1.0 mM pAzF test groups. 
The above results are consistent with a previous report where an even lower concentration (0.01 
mM) of unAA was sufficient for protein expression.7 Therefore, the concentration of unAA can 
be adjusted within a large dynamic range based on different experiment requirements, and should 
not be a limiting factor in our vaccine strategy.  
2.3 Summary and remarks 
In this chapter, we demonstrated the use of amber suppression machinery as an unnatural 
genetic switch to turn on and off HIV-1 replication through the addition or the clearance of an 
unAA. Based on this strategy, two generations of amber suppression-dependent HIV-1 variants 
have been constructed and examined. The first-generation vaccine variants contain one or more 
in-frame amber mutations within essential genes of HIV-1. Consequently, the biosynthesis of 
corresponding viral proteins becomes dependent on the presence of the exogenous amber-
suppressing aaRS/tRNA pair and an unAA. Since the host cells do not have the amber suppression 
machinery, the viruses can only complete one cycle of infection or replication and may not be able 
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to mount sufficient protective immune responses. To solve this problem, the aaRS-tRNA encoding 
gene was inserted onto HIV-1 genome to generate the second-generation all-in-one HIV-1 variants. 
Multicycle replication of HIV-1 has been achieved through co-localization of the amber 
suppression machinery and HIV-1 provirus in the same infected cells. These multicycle attenuated 
HIV-1 variants can be employed to mimic the prime-boost vaccine regimen. After obtaining 
desired immune responses with the prime, the replication of the vaccine strain can be switched off 
by simply withdrawing the unAA. Once a booster vaccination is needed, the replication of HIV-1 
can be turned on transiently by providing the unAA and turned off later. This approach can be 
potentially extended for the development of LAVs for other pathogens.  
Our strategy provides several advantages over conventional HIV-1 LAV strategies. The safety 
of Δnef-LAVs has been questioned due to their pathogenic potentials. Multiple deletions or 
mutations in accessory genes may improve the safety of these vaccine strains,145 but they usually 
lead to a significant reduction in protective efficacy due to decreased replication capacity. We 
prevented uncontrolled virus replication by introducing an unnatural genetic switch into HIV-1. 
The replication of our vaccine strains can be permanently switched off by simply discontinuing 
the administration of the unAA. In addition, our vaccine strains maintain the intact HIV-1 genome 
and all of the viral immunogens. The only changes are the substitutions of natural amino acids 
with their unnatural amino acid analogs at permissive positions as well as the insertion of a 
genomic copy of aaRS-tRNA encoding gene. Theoretically, these changes should not significantly 
reduce the vaccine efficacy. The immunogenicity of our vaccine strains can be further improved 
by the incorporation of immunogenic unAAs.21-23 
 One concern for all HIV-1 LAVs is the possibility to regain virulence during virus replication 
due to error-prone transcriptions. In our strategy, this can be prevented by the installation of 
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multiple amber stop codons. Based on our calculations, the possibility of reverting all amber 
codons to sense codons is approximately 1.0 × 10−2, 1.0 × 10−4, and 1.0 × 10−6 respectively (in 100 
years) when one, two, and three amber codons were used. In fact, this chance can be even lower. 
Based on a recent amber-suppression dependent influenza A vaccine, the escape frequencies in 
mammalian cells decreased from 1.0 × 10−8 to 1.2 × 10−10 and to less than 1.0 × 10−11  when one, 
two, and three ambers codons are presented.24 Another concern of our vaccine strategy is the 
genetic stability of the inserted aaRS-tRNA encoding gene, which may lose the control activity 
due to mutations or deletions. Although the loss of pAzFRS-tRNATyr cassette might occur in a very 
long term, during our experiments (2 weeks’ cultivation) we did not observe such event according 
to RT-PCR and DNA sequencing results. In fact, the loss of pAzFRS-tRNATyr function will result 
in a replication-incompetent strain, which can be beneficial in terms of safety.  
In summary, we have demonstrated that the replication and viability of HIV-1 can be precisely 
controlled by an unnatural genetic switch based on genetic code engineering. The ability to control 
the timing and duration of HIV-1 replication represents an important step towards the construction 
of a safe and effective live-attenuated HIV-1 vaccine. In addition, unAA mutagenesis of HIV-1 
viral proteins may enhance their biochemical or immunological properties, and facilitate the study 















Figure 5. An unnatural genetic switch for regulation of HIV-1 replication. (A) Amber mutations 
were installed in the essential genes of HIV-1. The replication of resulted HIV-1 variants can be 
turned on in the presence of unAA and exogenously expressed unnatural genetic switch 
(aaRS/tRNACUA pair). In the absence of unAA, the viral replication is turned off. Since host cells 
do not have unnatural genetic switch, the virus can only replicate for single-cycle. (B) A genomic 
copy of unnatural genetic switch was inserted onto HIV-1 genome to afford all-in-one HIV-1 
variants, the replication of which is under stringent control of the presence or absence of unAA.  
Since the aaRS/tRNACUA pair is co-expressed with essential viral proteins, these HIV-1 variants 
can undergo multi-cycle replication. (C) Natural and unnatural amino acids used in this chapter, 
namely: 1, p-azido-L-phenylalanine (pAzF); 2, p-iodo-L-phenylalanine (pIodoF); 3, p-acetyl-L-
phenylalanine (pAcF); 4, tyrosine; 5, o-nitrobenzoyl-tyrosine (ONBY); 6, o-nitrobenzyl-






Figure 6. Amber suppression of EGFP in 293T cells. (A) EGFP expression in the presence of 
pAzFRS/tRNATyr pair and 1 mM pAzF; (B) EGFP expression in the presence of pAzFRS/tRNATyr 
pair, but without pAzF; (C) Tandem-mass spectra of EGFP-Y40pAzF. The reduction product (4-
aminophenylalanine) of pAzF was detected exclusively at position 40 of EGFP.  





Figure 7. The HIV-1 genome organization. Abbreviations: MA, p17 matrix protein; CA, p24 
capsid protein; NC, nucleocapsid protein; SP1, Spacer peptide 1; SP2, Spacer peptide 2; LTR, long 
terminal repeat; PR, protease; RT, reverse transcriptase; IN, integrase. The red arrows indicated 
insertion sites for foreign genes.  
Reproduced with permission from “ACS Synthetic Biology, in press. Unpublished work copyright 










Figure 8. p24 assay after transfection with pSUMA variants and pAzFRS/tRNATyr
 
pair. (Well 1-6) 
Co-transfection of pAzFRS/tRNATyr
 
pair with the following pSUMA variants in the absence of 
pAzF: (well 1) MA-Y132; (well 2) RT-F216; (well 3) Tat-T20; (well 4) MA-A119; (well 5) RT-
F271; (well 6) RT-L365. (Well 8-13) Co-transfection of pAzFRS/tRNATyr
 
pair with the following 
pSUMA variants in the presence of 1 mM pAzF: (well 8) MA-Y132; (well 9) RT-F216; (well 10) 
Tat-T20; (well 11) MA-A119; (well 12) RT-F271; (well 13) RT-L365. (Well 7) negative control, 





Figure 9. p24 assay after transfection with pSUMA variants and pIodoFRS/tRNATyr or 
pAcFRS/tRNATyr pair. (Well 1-7) Co-transfection of pIodoFRS/tRNATyr pair with the following 
pSUMA variants in the presence of 1 mM pIodoF: (well 1) MA-Y132; (well 2) RT-F216; (well 3) 
Tat-T20; (well 4) MA-A119; (well 5) CA-L268; (well 6) RT-F271; (well 7) RT-L365. (Well 8-14) 
Co-transfection of pAcFRS/tRNATyr pair with following pSUMA variants in the presence of 1 mM 
pAcF: (well 8) MA-Y132; (well 9) RT-F216; (well 10) Tat-T20; (well 11) MA-A119; (well 12) 






Figure 10. Control the expression of EGFP with photocaged unAAs. (A) EGFP expression in the 
presence of the ONBY-RS/tRNAPyl pair and 0.4 mM ONBY; (B) EGFP expression in the presence 
of the ONBY-RS/tRNAPyl pair; (C) EGFP expression in the presence of the ONBK-RS/tRNAPyl 





Figure 11. Control the replication of HIV-1 by amber suppression.  
(A-H) Infection assays with TZM-bl cells. (A) MA-Y132 + TyrRS/tRNATyr pair; (B) MA-Y132; 
(C) RT-F216 + TyrRS/tRNATyr pair; (D) RT-L365 + TyrRS/tRNATyr pair; (E) MA-Y132 + 
pAzFRS/tRNATyr pair, with 1 mM pAzF; (F) MA-Y132 + pAzFRS/tRNATyr pair; (G) MA-A119 






Figure 12. Infection of TZM-bl with pSUMA-wt. 







Figure 13. Expression and infection with pNL-GI variants. 
(A) Fluorescence image of wild-type pNL-GI; (B) Fluorescence image of pNL-GI-N40TAG + 
pAzFRS/tRNATyr pair, with 1 mM pAzF; (C) Infection of TZM-bl cells with viruses collected from 
(A); (D) Infection of TZM-bl cells with viruses collected from (B).  






Figure 14. Infection of TZM-bl cells with pSUMA variants in the presence of TyrRS/tRNATyr pair. 
(A-D) Infection assay with TZM-bl cells. (A) PR-Y59 + TyrRS/tRNATyr pair; (B) MA-F44 + 





Figure 15. Control the replication of HIV-1 with an unnatural genetic switch. (A-C) Infection 
assay with TZM-bl cells. (A) pSUMA-wt; (B) PR-Y59 + pAzFRS/tRNATyr pair, with 1 mM pAzF; 
(C) MA-W36Q127 + pAzFRS/tRNATyr pair, with 1 mM pAzF. Scale bars, 200 nm. The doses used 
for infection are shown as TCID50 values. The wild-type pSUMA was diluted 4-fold and the 
pSUMA mutants were concentrated 15-fold in order to adjust the infectious dose of each variant 
to similar levels.  





Figure 16. Infection of TZM-bl cells with HIV-1-iGFP and HIV-1-NL-GI strains. 
Reproduced with permission from “ACS Synthetic Biology, in press. Unpublished work copyright 





Figure 17. Relative replication efficiency of four pNL4-3 variants. 
Reproduced with permission from “ACS Synthetic Biology, in press. Unpublished work copyright 






Figure 18. Construction and examination of HIV-AzFRS-tRNA variants. (A) The four HIV-
AzFRS-tRNA variants with different positions and orientations of tRNATyr; (B) Infectivity assay 
of the four HIV-AzFRS-tRNA variants and the parental pNL43-wt virus; (C) Functional assay of 
the inserted AzFRS-tRNATyr pair of the four HIV-AzFRS-tRNA variants and the parental pNL43-
wt virus in the presence of 1 mM pAzF.  
Reproduced with permission from “ACS Synthetic Biology, in press. Unpublished work copyright 






Figure 19. Infectivity assay of the pNL43-Trp36-AzFRS-tRNA-2 and the pNL43-Tyr59-AzFRS-
tRNA-2 mutants in the presence and the absence of pAzF. (A) Infection of TZM-bl cells with 
pNL43-Trp36-AzFRS-tRNA-2 and the pNL43-Tyr59-AzFRS-tRNA-2 mutants; (B) TCID50 
values and virion numbers.  
Reproduced with permission from “ACS Synthetic Biology, in press. Unpublished work copyright 








Figure 20. Viral RNA (vRNA) and DNA (vDNA) detection using RNAscope and DNAscope in 
situ hybridization (ISH). (A-F) In situ detection of HIV-1 vRNA. HIV-1 vRNA was detected using 
RNAscope ISH with V-HIV Clade B antisense probes and RNAscope 2.0 HD red reagent kit. (A) 
Positive control, ACH2 cells stimulated with PMA; (B) SupT1 cells infected with pNL43-Trp36-
AzFRS-tRNA-2 and in the presence of pAzF; (C) SupT1 cells infected with pNL43-Tyr59-
AzFRS-tRNA-2 and in the presence of pAzF; (D) Negative control, SupT1 cells without HIV-1 
infection; (E) SupT1 cells infected with pNL43-Trp36-AzFRS-tRNA-2 and in the absence of pAzF; 
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(F) SupT1 cells infected with pNL43-Tyr59-AzFRS-tRNA-2 and in the absence of pAzF. (G-L) 
In situ detection of HIV-1 vDNA. HIV-1 vDNA was detected using DNAscope ISH with V-HIV 
Clade B sense probes and RNAscope 2.0 HD red reagent kit. Arrows indicate the cells harboring 
HIV-1 vDNA (red dots). (G) Positive control, ACH2 cells; (H) SupT1 cells infected with pNL43-
Trp36-AzFRS-tRNA-2 and in the presence of pAzF; (I) SupT1 cells infected with pNL43-Tyr59-
AzFRS-tRNA-2 and in the presence of pAzF;(J) Negative control, SupT1 cells without HIV-1 
infection; (K) SupT1 cells infected with pNL43-Trp36-AzFRS-tRNA-2 and in the absence of 
pAzF; (L) SupT1 cells infected with pNL43-Tyr59-AzFRS-tRNA-2 and in the absence of pAzF. 
Scale bars, 20 μm.  
Reproduced with permission from “ACS Synthetic Biology, in press. Unpublished work copyright 






Table 2. Evaluation of the multi-cycle infectivity of the pNL43-Trp36-AzFRS-tRNA-2 and the 
pNL43-Tyr59-AzFRS-tRNA-2 mutants in the presence and the absence of pAzF. 
Reproduced with permission from “ACS Synthetic Biology, in press. Unpublished work copyright 













Figure 22. Relative expression levels of pAzFRS. (A)The pAzFRS mRNA level. (B) Infection of 
TZM-bl cells with pNL4-3 variants containing CMV promoter. (a) pNL43-Trp36-CMV-AzFRS-
tRNA-2, with 1 mM pAzF; (b) pNL43-Trp36-AzFRS-tRNA-2, with 1 mM pAzF; (c) pNL43-
Tyr59-CMV-AzFRS-tRNA-2, with 1 mM pAzF; (d) pNL43-Tyr59-AzFRS-tRNA-2, with 1 mM 
pAzF; (e) pNL43-Trp36 + pAzFRS plasmid, with 1 mM pAzF; (f) pNL43-Tyr59 + pAzFRS 
plasmid, with 1 mM pAzF. The pNL43-all-UAA variant was used as the parental plasmid for all 





permission from “ACS Synthetic Biology, in press. Unpublished work copyright 2017 American 
Chemical Society.”  
 
 
Figure 23. Expression and infection of pNL43 variants with two genomic copies of tRNATyr. 
(A) Fluorescence image of pNL43-AzFRS-2tRNA-F + pEGFP, with 1 mM pAzF; (B) 
Fluorescence image of pNL43-AzFRS-2tRNA-R + pEGFP, with 1 mM pAzF; (C) TZM-bl 










Figure 25. Suppression of an amber codon in EGFP in the presence of different concentration of 
pAzF. 293T cells were co-transfected with pAzFRS and pEGFP plasmids.  
Reproduced with permission from “ACS Synthetic Biology, in press. Unpublished work copyright 






Systematic Evolution and Study of Quadruplet Codon Decoding tRNAs 
Reproduced with permission from “Scientific Report. 2016, 6, a21898.” 
3.1 Introduction: Quadruplet codon decoding tRNAs for genetic code expansion  
Genetic code is the language that translates genetic information into proteins, which is 
essentially universal in all organisms. The canonical genetic code consists of 64 triplet codons that 
are used to encode the twenty natural amino acids and terminate polypeptide synthesis. In recent 
years, amber stop codon reassignment has enabled site-specific incorporation of unAAs into 
proteins in a variety of organisms.5,6,52 To date, more than 200 structurally and functionally 
distinctive unAAs have been genetically encoded. The ability to simultaneously incorporate 
different unAAs into target proteins at defined sites will vastly expand our tools for investigating 
protein structure and function, and for installing novel functions into biomolecules. However, the 
number of available nonsense triplet codons has severely hindered our ability to introduce different 
unAAs at multiple sites. Thus, more “blank” codons that have not been used to encode 
proteinogenic amino acids are needed.  
In theory, a quadruplet codon table would provide a total of 44=256 “blank” codons, which 
could be used to further expand the genetic code. Quadruplet codons (known as +1 frameshift) 
have been shown to be decoded by naturally occurring tRNA mutants and to incorporate natural 
amino acids.146-154 These tRNA mutants usually contain an extra nucleotide in the anticodon loop 
(8-bases instead of 7-bases). Following this rationale, unAA mutagenesis has been achieved using 
quadruplet codons and chemically aminoacylated tRNA bearing an expanded anticodon loop in a 
cell-free translation system.155-158 Simultaneous incorporation of two distinctive unAAs has been 
realized in E. coli by decoding a quadruplet codon and an amber stop codon with two mutually 
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orthogonal aaRS/tRNA pairs.33,67 Nevertheless, genetically encoding multiple unAAs is still at an 
early stage of development and requires further improvement with respect to decoding efficiency 
and the availability of novel quadruplet anticodon-codon pairs.  
Recently, we54 and others30 reported a general approach to improve the quadruplet codon 
decoding efficiency with AGGA, UAGA, CUAG, and AGUA codons through tRNA engineering. 
Following the same strategy, we systematically evolved tRNAs for UAGN (N = A, G, U, or C) 
codon decoding in a genomically recoded E. coli strain C321.ΔA (with all 321 UAG codons 
changed to UAA and an RF1 knock-out).66 We first constructed a tRNA library, in which each 
tRNA mutant harbored an expanded anticodon stem loop (ASL) with saturated mutations at 
positions 29, 30, 31, 32, 33, 33.5 and positions 38, 39, 40, 41. The library was then subjected to 
antibiotic-based positive selection to isolate functional library members. The selected library 
members were sequenced and validated through fluorescence-based assays. We also characterized 
the efficiency and fidelity of quadruplet codon decoding of the evolved tRNAs. Our efforts on 
engineering UAGN decoding tRNAs may help both uncover the mechanism of quadruplet codon 
decoding and broaden the application of genetic code expansion with quadruplet codons.  
3.2 Approaches 
3.2.1 tRNA (with an expanded anticodon loop) library construction and selection for UAGN 
(N = A, G, U, C) codon decoding.   
We chose tRNACUA
Pyl, a naturally occurring amber suppressor tRNA from Methanosarcina 
maize as a model for investigating quadruplet codon decoding. Based on the crystal structure, 
PylRS does not directly interact with the anticodon loop of tRNACUA
Pyl.55 This may allow 
tRNACUA
Pyl to be evolved for quadruplet codon decoding by introducing mutations at the 
anticodon stem loop. In order to identify tRNANCUA
Pyl variants that are able to decode UAGN (N= 
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A, G, U or C) codons, we created a tRNANCUA
Pyl (NCUA-11) library in which six nucleotides in 
the anticodon stem (positions 29, 30, 31, 39, 40, and 41), and five nucleotides in the anticodon 
loop (positions 32, 33, 33.5, 37, and 38) were completely randomized (Figure 26A). The actual 
library size was 5.2 ×106 which covered >99% of the theoretical diversity. Multiple research 
groups have shown that four-base complementarity is nonessential but highly favored in 
quadruplet codon decoding.159-161 The insertion of a randomized nucleotide at position 33.5 
(between U33 and C34; the first base of anticodon) in tRNACUA
Pyl may allow us to assess whether 
complete quadruplet codon-anticodon base-pairing is required for UAGN decoding. 
To identify functional tRNANCUA
Pyl variants that can suppress UAGN codons, we constructed 
positive selection reporters (Figure 26B) that contain an in-frame quadruplet codon of interest in 
the chloramphenicol acetyltransferase gene (pREP-BocKRS-UAGN). The selection was 
conducted by growing cells that contained the tRNANCUA
Pyl library, BocKRS (a PylRS derivative 
that charges Nε-(tert-butyloxy-carbonyl)-L-lysine (BocK) onto tRNACUA
Pyl), and chloramphenicol 
acetyltransferase reporter gene in the presence of varying concentration of chloramphenicol (from 
34 to 75 μg/mL) and 5 mM BocK. The surviving cells were replicated on LB agar plates containing 
a range of different concentrations of chloramphenicol (50, 75, and 100 μgmL-1) in the presence 
or absence of BocK. A clone that grew at 100 μgmL-1 chloramphenicol in the presence of BocK 
but did not grew at 50 μgmL-1 chloramphenicol in the absence of BocK were considered a hit. 
Multiple hits were selected for UAGA, UAGU, and UAGG codons. We were not able to obtain a 
hit for UAGC decoding after several attempts. From each selection, three hits that conferred the 
highest level of chloramphenicol resistance were further characterized. The selected tRNANCUA
Pyl 
hits were named UAGN-X, where N represents A, G, or U; and X represents the hit number.  
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3.2.2 Characterization and validation of evolved tRNAs.  
We examined the efficiency and fidelity of quadruplet codon decoding tRNAs using a 
fluorescence-based assay. The four targeting quadruplet codons, UAGA, UAGG, UAGU, and 
UAGC, were inserted at a permissive site in GFPuv encoding gene to yield GFPuv-Asn149UAGA, 
GFPuv-Asn149UAGG, GFPuv-Asn149UAGU, and GFPuv-Asn149UAGC reporters. The 
encoding gene for each tRNANCUA
Pyl mutant was introduced into a corresponding GFPuv-
Asn149UAGN reporter to generate a pGFPuv-NCUA-X plasmid (N=A, G, U, or C; X is hit 
number). If a tRNA can decode a quadruplet codon of interest, a full-length GFPuv is produced. 
Therefore, the intensity of GFPuv fluorescence can be directly correlated to the quadruplet codon 
decoding efficiency of a tRNA mutant.  As a control, the encoding gene for tRNANCUA
Pyl-wt (N=A, 
G, U, or C), in which the triplet CUA anticodon was replaced with a quadruplet anticodon of 
interest, was also introduced into the reporters to generate pGFPuv-NCUA-wt plasmids.   
pGFPuv-NCUA-X and pGFPuv-NCUA-wt plasmids were each transformed into C321.ΔA 
cells that contained pBK-BocKRS plasmid. The cells were first grown to saturation at 30 °C and 
then subcultured in fresh LB medium containing 0.1 mM IPTG with or without 5 mM BocK. As 
shown in Figure 27, a significant enhancement in quadruplet codon decoding efficiency was 
observed with all mutants when BocK was supplemented. The best three hits, UAGA-1, UAGU-
1 and UAGG-2 displayed approximately 55, 9, and 40 fold-improvement in quadruplet codon 
decoding in comparison to the corresponding tRNANCUA
Pyl-wt. The suppression efficiency of 
UAGA and UAGG codons was much higher than that of the UAGU codon. In the absence of 
BocK, the fluorescence of these mutants was negligible, indicating that tRNANCUA
Pyl mutants were 
selectively charged with BocK by BocKRS but not with any natural amino acids by BocKRS or 
endogenous aaRSs. Although we did not obtain a hit for the UAGC codon, we tested the efficiency 
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of UAGC codon decoding by tRNAGCUA
Pyl-wt and a few tRNA hits. No detectable decoding was 
observed.  
GFPuv mutants from the above experiments were purified with Ni Sepharose Fast 6 resins 
(Figure 28). Consistent with the observation in the fluorescence assays, suppression of the UAGA 
codon by tRNA hit UAGA-1 resulted in the highest protein yield (~54 mg/L). Suppression of the 
UAGG codon by tRNA hit UAGG-2 also led to a large protein yield (~21 mg/L). The lowest yield 
(~9 mg/L) was obtained with tRNA hit UAGU-1 for UAGU decoding. The GFPuv-Asn149BocK 
samples were then subjected to in-gel digestion for mass spectrometry analysis. At position 149 of 
GFPuv, only BocK or Lys (after cleavage of Boc group from BocK) was detected (Figure 29), 
suggesting high fidelity of the evolved tRNANCUA
Pyl mutants for quadruplet codon decoding. 
3.2.3 Incorporation of other unAAs using the evolved tRNAs. 
Since the ASL of tRNACUA
Pyl does not directly interact with PylRS,162,163 the evolved 
tRNANCUA
Pyl mutants can be potentially recognized by other PylRS derivatives with different 
amino acid specificity. To demonstrate that tRNANCUA
Pyl mutants can be used to incorporate a 
range of unAAs in response to UAGN (N= A, G, or U) codons, we randomly chose two unAAs, 
3′-azibutyl-N-carbamoyl-lysine (AbK)164 and o-nitrobenzyl-oxycarbonyl-Nε-L-lysine (ONBK)125 
for the study. Cells containing UAGA-1, UAGU-1 and UAGG-2 tRNA mutants were grown in the 
presence or absence of 1 mM AbK (Figure 30) and 1 mM ONBK (Figure 31), respectively. All 
of the selected hits displayed significant enhanced quadruplet codon decoding efficiency with both 
unAAs compared to tRNANCUA
Pyl-wt. The relative decoding efficiency at UAGA, UAGG, and 
UAGU codons by BocK, AbK, and ONBK remained consistent, though in general, the 
incorporation of BocK and AbK was more efficient than ONBK. Notably, the UAGU-1 mutant 
led to a significant increase in UAGU codon decoding efficiency when pairing with AbKRS and 
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without further changes in the nucleotide sequence of tRNA, which suggested that the nature of 
aaRS also affected quadruplet codon decoding efficiency.  
3.2.4 Analysis of the evolved tRNA mutants. 
Due to potential post-transcriptional modifications and stable secondary structures, it is hard 
to directly sequence tRNA transcripts through standard methods. Therefore, we isolated and 
sequenced the plasmid DNA that encode evolved tRNANCUA
Pyl mutants. The sequencing results 
for these tRNANCUA
Pyl hits are shown in Table 3. Surprisingly, a 5’-UCUA-3’ anticodon was 
conserved in all the hits. In addition, tRNANCUA
Pyl mutants sharing the same sequences were 
identified from different selections, such as UAGA-2 and UAGU-3, UAGG-1 and UAGU-1, 
UAGG-3 and UAGU-2. In fact, all UAGU variants were also found in selections against UAGA 
and UAGG. U33 and A37 seemed to be essential for UAGN decoding since no mutations were 
found at these two positions. All the evolved tRNA variants contained A31G and U39C mutations. 
The replacement of the A31-U39 pair with the G31-C39 pair likely strengthened the anticodon 
stem region that is directly connected with the anticodon loop. Most of these mutants did not have 
Watson-Crick base-pairing at position 29-41 or 30-40. The C40U mutation led to a weaker base-
pairing interaction at position 30-40. These mutations in the ASL may result in a favorable 
conformational change, which allows tRNA variants to be correctly positioned in the ribosome A 
site and translocated during peptide elongation.  
3.2.5 Cross-decoding among UAGN codons.   
Since the three best hits, UAGA-1, UAGU-1, and UAGG-2 all contained 5’-UCUA-3’ 
anticodon, we cross-tested the decoding efficiency of the quadruplet codons that were not selected. 
New fluorescence reporter plasmids pGFPuv-Asn149UAGN-BocKRS were constructed to 
simplify the experimental design. The evolved tRNANCUA
Pyl variants were transformed into cells 
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containing the corresponding fluorescence reporters. All the tRNA variants showed some level of 
cross-activity against other codons. The UAGG-2 mutant displayed the highest cross activity 
(Figure 32) with the UAGA codon. It showed approximately 87% suppression efficiency relative 
to the UAGA-1 mutant. This mutant showed approximately 122% activity relative to the UAGU-
1 mutant with the UAGU codon. The UAGA-1 mutant was relatively more selective for the UAGA 
codon. Interestingly, UAGU-1 displayed a much higher suppression efficiency towards the UAGA 
and UAGG codons than to its cognate UAGU codon.   
3.2.6 tRNA (with regular 7-base anticodon loop) library construction and selection for 
UAGN (N = A, G, U, C) decoding. 
Since UAGN decoding does not require a perfect complementarity at the fourth base of the 
anticodon-codon, we sought to investigate whether tRNAs with regular 7-base anticodon loops 
were capable of decoding UAGN codons. We constructed a tRNACUA
Pyl library (CUA-10) in 
which six nucleotides in the anticodon stem (positions 29-31, 39-41) and four nucleotides in the 
anticodon loop (positions 32,33,37,38) were completely randomized (Figure 26A). The actual 
library size was 8.7 × 106, which covered >99% theoretical diversity of the library. The resulting 
library was subsequently subjected to positive selections against UAGA, UAGG, UAGU, and 
UAGC codons, respectively, using pREP-BocKRS-UAGN reporters. We did not identify any hits 
from the selections. These results suggested that an expanded anticodon loop was essential for 
UAGN decoding. 
3.2.7 Cross-decoding against UAG codons. 
Since the last three bases of 5’-NCUA-3’ anticodon of tRNANCUAPyl variants can form 
Watson-Crick base-pairing with the amber UAG codon, they might be able to decode the amber 
codon. To examine this possibility, a fluorescence reporter pGFPuv-Asn149UAG-BocKRS was 
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constructed. The amber suppression efficiency of tRNA variants, UAGA-1, UAGU-1, and UAGG-
2 were examined by the expression of full-length GFPuv in the presence of 5 mM BocK. As shown 
in Figure 33, UAGA-1 and UAGG-2 mutants displayed a good selectivity towards UAGA and 
UAGG codons. The UAGU-1 mutant showed a similar level of suppression efficiency towards 
both UAGU and UAG codons. This may result from low decoding efficiency of UAGU-1 towards 
the UAGU codon. All three mutants showed a significant lower amber suppression efficiency than 
tRNACUA
Pyl (decreased by approximately 40-60 folds).  
3.2.8 Quantification of UAGN decoding efficiency with fluorescence reporters 
To quantitatively analyze the decoding efficiency of the hits against UAGN (N= A, G, U, or 
C) codons versus UAG codon, we generated two series of fluorescence reporters, pStrepII-GFPuv-
UAGN and pStrepII-GST-X-GFPuv. The pStrepII-GFPuv-UGAN reporters (Figure 34A) 
contained one copy of GFPuv gene with a quadruplet codon of interest at position 149 and two 
additional mutations GCA154GCT, and GAC155GAT. As shown in Figure 34A, only if UAGN 
is decoded as a quadruplet codon, can a full-length GFPuv be expressed. On the other hand, if 
UAGN is translated as an ordinary three-base, then a premature termination at position 155 will 
result in a truncated form of GFPuv, which is not fluorescent. Since a StrepII-tag was fused to the 
N-terminus of GFPuv, the expression levels of both the full-length and truncated protein can be 
simultaneously quantified by western blot (Figure 34B). We observed the formation of both full 
length and truncated GFPuv in E. coli GeneHogs, but not in C321. ΔA (Data not shown). 
The pStrepII-GST-X-GFPuv reporters contained a short linker G*ADI (* represents tyrosine 
encoded by UAG, or BocK encoded by UAGA) between GST and GFPuv protein (Figure 35A). 
Therefore, when UAGA is correctly decoded, a GST-GFPuv fusion protein (51 kDa) is produced. 
If the first three bases of UAGA are decoded as a triplet codon, then a GST with three additional 
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amino acids at the C-terminus (25 kDa) is generated. We first titrated the GST-GFPuv fusion 
protein (produced by pStrepII-GST-UAC-GFPuv) and GST protein (produced by pStrepII-UAG-
GFPuv) using western blot (Figure 35B). Surprisingly, the signals detected from GST-GFPuv 
were much weaker than from the same amount of GST. One plausible explanation is a less efficient 
transfer of GST-GFPuv than GST from the SDS-PAGE gel to the nitrocellulose due to its larger 
size. Next, we compared the decoding efficiency of tRNAs UAGA-1 and UAGA-wt towards the 
UAGA codon in cell lysates. The expression of GST-GFPuv was almost non-detectable in both 
samples (Figure 35C). Strikingly, although the positive control (pStrepII-GST-UAG-GFPuv with 
tRNACUA
Pyl) showed a strong fluorescence, the expression of GST-GFPuv was not detected by 
western-blot. Since this method led to a discrepancy in signal outputs for two target proteins, new 
reporters based on different tags or reporting genes are needed.  
3.3 Summary and remarks 
In this chapter, we presented the first example of systematic evolution of tRNAs for UAGN 
codon (N= A, G, U, or C) decoding in a genetically recoded E. coli strain C321.∆A. By fully 
randomizing selected nucleotides in the ASL of the parental tRNA, we successfully engineered 
several tRNA variants that displayed a significantly higher efficiency in UAGN decoding in 
comparison to their corresponding wild-type controls. The best hit (UAGA-1) led to a 55-fold 
improvement in UAGA decoding efficiency in comparison to tRNAUCUA
Pyl-wt. This hit also 
showed a significant decoding activity towards the UAGA codon in E. coli GeneHogs, indicating 
that this tRNA can overcome the competition from RF1 at the ribosome A site. In addition, some 
of the hits contained convergent sequences and displayed cross-activity against the quadruplet 
codons that they were not selected against.  
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Our data suggests that an expanded anticodon loop (8-base) is required for efficient UAGN 
decoding. However, a complete four-base pair is not essential for UAGN decoding. This result 
cannot be easily explained using classical models, the yardstick model or the slippery model 
(Figure 36)165,166 for quadruplet codon decoding (+1 frameshift). The yardstick model states that 
the anticodon forms a complete four-base interaction with the quadruplet codon at the ribosome A 
site, and a subsequent quadruplet translocation from the A site to the P site causes the +1 frameshift. 
However, a few evolved tRNANCUA
Pyl variants apparently cannot form a complete quadruplet 
codon-anticodon interaction at the A site. Alternatively, the slippery model proposes a triplet 
anticodon-codon interaction at the A site and a triplet translocation from the A site to the P site 
followed by slippage of the mRNA by one base and re-paring between the anticodon and the 
mRNA. In our UAGN study, the re-paring event is unlikely to happen between UAGN codons 
(N=A, G, or U) and 5’-UCUA-3’ anticodon in tRNANCUAPyl variants due to the lack of Watson-
Crick base-pairing after the re-paring event. Therefore, we proposed a modified slippery model 
for UAGN decoding (Figure 37). It is likely that the extra nucleotide U33.5 in tRNANCUA
Pyl 
interacts with the fourth base of UAGN sequence in the P site which induces steric hindrance to 
the incoming tRNA in the A site and facilitates the +1 frameshift.  
In summary, we evolved a set of tRNAs that are capable of incorporating different unAAs in 
response to UAGN codons. We also confirmed the essential role of an expanded anticodon loop 
for efficient UAGN decoding. In addition, we demonstrated that four-base complementarity was 
not required for UAGN decoding. This work will facilitate the mechanistic study of quadruplet 




3.4 Figures and tables 
 
 
Figure 26. Library construction and selection for UAGN-decoding tRNANCUA
Pyl variants. (A) 
Construction of tRNACUA
Pyl (CUA-10) library and tRNANCUA
Pyl (NCUA-11) library (N= A, G, U, 
or C). Mutation sites are highlighted in red and the three-base anticodon of wild-type tRNAPyl is 
in blue. (B) The chloramphenicol acetyltransferase reporter with Gln98UAGN (N = A, G, U, or C) 
mutations. Only cells containing tRNANCUA
Pyl variants that can efficiently decode UAGN codons 





Figure 27. GFPuv expression in celles containing tRNANCUA
Pyl variants. GFPuv expression was 
conducted in cells containing tRNANCUA
Pyl mutants or tRNANCUA
Pyl-wt, BocKRS, and 
corresponding GFPuv-Asn149UAGN reporter in the presence or absence of 5 mM BocK. 
Fluorescence intensity was normalized to cell density. The data shown was an average of triplicate 
measurements.  






Figure 28. Purification of GFPuv-Asn149BocK mutants. (A) Lane 1, GFPuv mutant expressed in 
the presence of GFPuv-Asn149UAGA and tRNA UAGA-1, with 5 mM BocK; Lane 2, GFPuv 
mutant expressed in the presence of GFPuv-Asn149UAGU and tRNA UAGU-1, with 5 mM BocK; 
Lane 3, GFPuv mutant expressed in the presence of GFPuv-Asn149UAGG and tRNA UAGG-2, 
with 5 mM BocK. (B) Protein yields in (A). 






Figure 29.  Mass spectrometry analysis of GFPuv containing BocK at position 149. (A) Suppress 
UAGU codon; (B) Suppress UAGG codon; (C) Suppress UAGA codon. The amino acid sequence 
of the peptide fragment, LEYNYNSHBocKVYITADK, from mutant GFPuv containing Boc-Lys 
is shown on top.  Two mass speaks were observed.  The (M + 2H) 2+ peak corresponds to 
LEYNYNSHBocKVYITADK that contains an intact BocK residue at position 149.  The (M + 3H) 
3+ peak corresponds to LEYNYNSHKVYITADK that contains a lysine residue at position 149 
due to the loss of Boc group under the mass spectrometry conditions. (Note: The BocKRS cannot 
charge the tRNA with lysine.  The observed peptide that contains a lysine at position 149 must be 
derived from the cleavage of the Boc group). 






Figure 30. UAGN codons decoding with AbK. GFPuv expression was conducted in cells 
containing tRNANCUA
Pyl mutants or tRNANCUA
Pyl-wt, AbKRS, and corresponding GFPuv-
Asn149UAGN reporter in the presence or absence of 1 mM AbK. Fluorescence intensity was 
normalized to cell density. The data shown was an average of triplicate measurements.  






Figure 31. UAGN codons decoding with ONBK. GFPuv expression was conducted in cells 
containing tRNANCUA
Pyl mutants or tRNANCUA
Pyl-wt, ONBK-RS, and corresponding GFPuv-
Asn149UAGN reporter in the presence or absence of 1 mM ONBK. Fluorescence intensity was 
normalized to cell density. The data shown was an average of triplicate measurements.  






Table 3. Sequences of tRNANCUA
Pyl variants that have improved UAGN decoding 
efficiency. 






Figure 32. Cross-activity of tRNANCUA
Pyl variants among UAGN codons. GFPuv expression was 
conducted in cells containing tRNANCUA
Pyl mutants, BocKRS, and corresponding GFPuv-
Asn149UAGN-BocKRS reporters in the presence of 5 mM BocK. Fluorescence intensity was 
normalized to cell density. The data shown was an average of triplicate measurements.  






Figure 33. UAGN and UAG codon decoding efficiency of tRNANCUA
Pyl variants. GFPuv 
expression was conducted in cells contained tRNANCUA
Pyl mutants, BocKRS, and pGFPuv-
Asn149UAG or pGFPuv-Asn149UAGN reporters in the presence of 5 mM BocK. Fluorescence 
intensity was normalized to cell density. The data shown was an average of triplicate 
measurements.  






Figure 34. Quantification of UAGN decoding efficiency with pStrepII-GFPuv-UAGN reporters. 
(A) Partial DNA sequence of GFPuv-wt and GFPuv-UAGN. Quadruplet codon decoding at 
position 149 leads to a full length GFPuv (27 kDa). Triplet codon decoding at position 149 leads 
to a truncated GFPuv (17 kDa). (B) Western blot of cell lysates containing pStrepII-GFPuv-UAGN 
(N=A, G, U, or C) reporters and tRNA variant UAGA-1. Lane 1, pStrepII-GFPuv-UAGA + tRNA 
UAGA-1, with 5 mM BocK; Lane 2, pStrepII-GFPuv-UAGU + tRNA UAGA-1, with 5 mM BocK; 
Lane 3, pStrepII-GFPuv-UAGG + tRNA UAGA-1, with 5 mM BocK; Lane 4, pStrepII-GFPuv-






Figure 35. Quantification of UAGN decoding efficiency with pStrepII-GST-X-GFPuv reporters. 
(A) DNA sequence of the linker region, X represents UAC, UAG, or UAGA. Quadruplet codon 
decoding at linker-UAGA leads to a GST-GFPuv fusion protein (51 kDa). Triplet codon decoding 
at linker-UAGA leads to a GST protein (25 kDa). (B) Western blot GST-GFPuv and GST titration. 
(C) Western blot of cell lysates containing pStrepII-GST-X-reporter and tRNA variants. Lane 1, 
pStrepII-GST-UAGA-GFPuv + tRNA UAGA-wt, with 5 mM BocK; Lane 2, pStrepII-GST-
UAGA-GFPuv + tRNA UAGA-1, with 5 mM BocK; Lane 3, pStrepII-GST-UAG-GFPuv + 
tRNACUA





Figure 36. Two classical models for quadruplet codon decoding. (A)Yardstick model; (B) 





Figure 37. A new model for quadruplet decoding (+1 frameshift). This model features a triplet 
translocation followed by a quadruplet anticodon-codon interaction in the P site of ribosome. 










Development of A General Approach to Evolve Aminoacyl-tRNA synthetase for Efficient 
Nonsense Codon Suppression 
Reproduced with permission from “ACS Synthetic Biology. 2015, 4, 207. Copyright 2015 
American Chemical Society.” 
4.1 Introduction:  Evolution of aminoacyl-tRNA synthetase for more efficient unAA 
incorporation 
Methanococcus jannaschii-derived tyrosyl-tRNA synthetase (MjTyrRS) and tyrosyl-tRNA 
(MjtRNATyr) pair has been extensively used for the genetic incorporation of aromatic unAAs in E. 
coli.6 To create a highly efficient and specific MjTyrRS/MjtRNATyr pair for unAA incorporation, 
several requirements need to be fulfilled: (1) an accurate and efficient aminoacylation of 
MjtRNATyr with a unique unAA by its cognate MjTyrRS; (2) no cross activity between the unAA-
specific MjTyrRS/MjtRNATyr pair and endogenous aaRS/tRNA pairs; (3) favorable interaction 
between the MjTyrRS/MjtRNATyr pair and the host translational machinery; and (4) nonsense 
codon (e.g., amber nonsense codon or quadruplet codons) decoding capacity of the charged 
MjtRNATyr.  
In previous studies, the evolution of MjTyrRS has focused on altering its specificity towards 
unAAs with different chemical structures and functions. The classical evolution approach takes 
two steps.2,4,11,44,45,167 The first step is to create a MjTyrRS library in which key residues within 
the amino acid recognition site are fully randomized. The second step involves consecutive rounds 
of in vivo selection to identify library members with desirable properties. Generally, a toxic gene 
is exploited in the negative selection to remove unspecific MjTyrRS variants that recognize natural 
amino acids.  In the positive selection, functional MjTyrRS hits that can decode nonsense codon 
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in an antibiotic resistance gene (or other selectable markers) are enriched. The order and number 
of positive and negative selections can be adjusted based on different experiment needs to obtain 
the best MjTyrRS variants. Following the above approach, a variety of MjTyrRS variants that 
possess good fidelity and high efficiency for unAA incorporation have been successfully identified.  
In the meantime, MjtRNATyr has been engineered to allow efficient amber suppression. The 
first base of the anticodon of wild-type MjtRNATyr (MjtRNAGUA
Tyr), G34, was mutated to C34 to 
generate an amber suppressor MjtRNATyr variant (MjtRNACUA
Tyr).1 The orthogonality of 
MjtRNACUA
Tyr was then further improved through directed evolution.3 However, based on an in 
vitro study, the aminoacylation efficiency of MjtRNACUA
Tyr by MjTyrRS was significantly lower 
than that of MjtRNAGUA
Tyr,168 which is undesired in unAA incorporation. According to an X-ray 
crystallography study (Figure 38), G34 plays a critical role in anticodon recognitions. The base of 
G34 is sandwiched between Phe261 and His283, and N1 and N2 of G34 form hydrogen bonds 
with Asp286 in MjTyrRS.32,87,169 Therefore, G34C mutation in MjtRNACUA
Tyr may lead to lower 
aminoacylation activity due to suboptimal anticodon recognition by MjTyrRS. A more 
comprehensive understanding of the interaction between the anticodon of MjtRNACUA
Tyr and the 
anticodon binding pocket of MjTyrRS may facilitate an improvement in unAA incorporation 
efficiency. In a prior report, it was demonstrated that MjTyrRS with an Asp286Arg mutation in 
the anticodon binding pocket had a higher aminoacylation rate and amber suppression 
efficiency.169 However, no systematic evolution at the anticodon recognition site of MjTyrRS has 
been reported.  
In this work, we utilized a directed evolution approach to identify MjTyrRS variants that 
displayed higher unAA incorporation efficiency. To create MjTyrRS libraries, four residues 
(Phe261, His283, Met285, and Asp286) that are proximal to C34 were fully randomized. Through 
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multiple rounds of selections, we obtained a collection of MjTyrRS variants with significantly 
improved unAA incorporation efficiency. The mutations in the evolved MjTyrRS variants were 
found to be specific for each unAA and could not be functionally transferred. In addition, the unAA 
incorporation efficiency has been further improved by combining our evolved MjTyrRS variants 
with a previously reported MjtRNACUA
Tyr mutant. This evolution approach will not only enhance 
the performance and utility of current unAA incorporation system, but also facilitate the discovery 
of highly selective and efficient aaRSs for novel unAAs. Our study can be theoretically extended 
to improving the incorporation efficiency of unAA against other nonsense codons, such as 
quadruplet codons.  
4.2 Approach 
4.2.1 pAcFRS library construction and selection for improving the incorporation efficiency 
of pAcF 
Site-specific incorporation of p-acetyl-L-phenylalanine (pAcF) that contains a keto group 
provides a useful tool for protein modifications and bio-conjugation.45,79,130 To improve the 
incorporation efficiency of pAcF, we constructed a pAcFRS library, in which residues Phe261, 
His283, Met285 and Asp286 in the anticodon recognition pocket of wild-type pAcFRS (referred 
to as pAcFRS-wt hereafter) were randomized into all possible combinations of amino acids.170 
Complete randomization was achieved by overlapping PCR with synthetic oligonucleotide primers 
containing NNK (N= A, G, U, or C; K= U or G) codons. We confirmed a coverage greater than 
the 99% theoretical diversity of the library.  
The resulting library was subjected to a positive selection using a dual-reporter (pREP) that 
contains amber mutations in the encoding genes for chloramphenicol acetyltransferase (Cm-
Asp112UAG) and T7 RNA polymerase (RNAP-Gln107UAG) (Figure 39). The positive selection 
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was conducted in the presence of pAcFRS library, MjtRNACUA
Tyr, and the dual-reporter, with 1 
mM pAcF and chloramphenicol. Only cells containing pAcFRS mutants that can charge either 
pAcF or natural amino acids onto MjtRNACUA
Tyr survived. Plasmids that encode pAcFRS mutants 
were isolated from the surviving cells and subjected to a negative selection in the absence of pAcF. 
A toxic barnase gene containing two amber mutations (Gln2UAG and Asp44UAG) was used. The 
pAcFRS mutants that could recognize natural amino acids led to the expression of full-length 
barnase and subsequent cell death. Conversely, cells containing orthogonal pAcFRS mutants 
survived. The clones that survived from two rounds of positive selection and one round of negative 
selection were screened for chloramphenicol resistance in the presence or absence of 1 mM pAcF. 
The clones that survived at 150 μg/mL chloramphenicol in the presence of 1 mM pAcF and that 
did not grow at 75 μg/mL chloramphenicol in the absence of pAcF was further characterized. 
Mutants pAcFRS-8G and pAcFRS-12B conferred the fastest growth rate in the presence of 
chloramphenicol and the brightest GFP fluorescence (driven by T7 RNAP). Another mutant 
pAcFRS-2B showed a relatively lower amber suppression efficiency. 
To determine whether incorporation efficiency of pAcF can be improved using the obtained 
mutants, each of the plasmids encoding pAcFRS-8G, pAcFRS-12B, pAcFRS-wt and pAcFRS-
D286R was transformed into E. coli GeneHogs containing a GFP reporter with an amber mutation 
at a permissive site (GFPuv-Asn149UAG). As shown in Figure 40, both pAcFRS-8G and 
pAcFRS-12B mutants displayed significant improvements in the incorporation efficiency of pAcF 
in comparison to the pAcFRS-wt and pAcFRS-D286R controls.169 The mutations for these evolved 
pAcFRS derivatives are listed in Figure 40. The results show that the stacking interactions at 
position 34 with Phe261 and His283 was not essential for the recognition of MjtRNACUA
Tyr by 
MjTyrRS variants. Interestingly, residues Met285 and Asp286 were mutated into smaller amino 
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acids, which contradicted our expectation that larger amino acids are needed to fill the anticodon-
binding pocket caused by the G34C mutation. pAcFRS-8G was chosen for further characterization 
since it displayed the highest amber suppression efficiency and better reproducibility.  
4.2.2 Attempts to transfer the beneficial mutations to other aminoacyl-tRNA synthetases  
MjTyrRS derivatives that recognize different unAAs generally share a conserved anticodon-
binding pocket. We examined whether the beneficial mutations observed in pAcFRS-8G could be 
directly transferred to other MjTyrRS variants to improve the incorporation efficiency of unAAs. 
We examined BpaRS11 (a MjTyrRS derivative that specifically recognizes p-benzoyl-L-
phenylalanine, or Bpa), sTyrRS47(a MjTyrRS derivative that specifically recognizes sulfotyrosine, 
or sTyr),  pIodoFRS171 (a MjTyrRS derivative that specifically recognizes p-iodo-L-phenylalanine, 
or pIodoF), and pAzFRS44 (a MjTyrRS derivative that specifically recognizes p-azido-L-
phenylalanine, or pAzF). BpaRS-8G, sTyrRS-8G, pIodoFRS-8G, and pAzFRS-8G mutants were 
constructed by transplanting the Phe261Gly, His283Leu, Met285Val, and Asp286Gln mutations 
from pAcFRS-8G into the corresponding MjTyrRS variants. There was no obvious enhancement 
in the incorporation efficiency of Bpa, pIodoF, or pAzF after installation of the beneficial 
mutations according to GFPuv-based fluorescence assay (Figure 41). The incorporation efficiency 
of sTyr was dramatically decreased. These results suggest that the recognition of an anticodon and 
the recognition of unAA are mutually dependent.  
4.2.2 BpaRS library construction and selection for improving the incorporation efficiency of 
Bpa 
Next, we investigated whether the evolution of the BpaRS at anticodon binding pocket can 
improve the incorporation efficiency of Bpa. To achieve this, a BpaRS library was constructed by 
fully randomizing residues Phe261, His283, Met285 and Asp286. The BpaRS library was screened 
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following the same selection strategy for pAcFRS. Three hits (BpaRS-8E, BpaRS-11D, BpaRS-
11H) displayed better incorporation efficiency than BpaRS-wt. BpaRS-8E showed the best 
incorporation efficiency (Figure 42). BpaRS-8E and BpaRS-11D, which had a convergent amino 
acid sequence, displayed relatively lower amber suppression efficiency than BpaRS-8E. 
Sequencing results showed that the stacking interaction between C34 and residues Phe261 and 
His283 was not required for anticodon recognition. Met285 of the selected BpaRS variants was 
replaced with smaller amino acids. In BpaRS-11D and BpaRS-11H, the negatively charged 
Asp286 remained unchanged or was mutated to a positively charged Arg. This was consistent with 
a previous finding that the Asp286Arg mutation can improve aminoacylation activity and amber 
suppression efficiency.95,169  
4.2.3 sTyrRS library construction and selection for improving the incorporation efficiency 
of sTyr 
Inspired by our success in evolving pAcFRS and BpaRS, we constructed a sTyrRS library in 
which the same set of residues (Phe261, His283, Met285, and Asp286) were fully randomized. 
The resulting library was subjected to multiple rounds of positive and negative selections to 
identify desirable sTyrRS variants. Two hits (sTyrRS-2A, sTyrRS-5A) displayed a slight 
enhancement in amber suppression efficiency compared to sTyrRS-wt (Figure 43). Again, the 
mutations at position 261 and 283 suggested that the stacking interaction required for the wild-
type MjtRNAGUA
Tyr was no longer required for the amber suppressor MjtRNACUA
Tyr. Since 
position 285 was mutated to smaller amino acids in all selections, we concluded that this position 
might not directly engage in anticodon recognition. Amino acids with shorter side chains were also 
observed at position 286.  
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4.2.4 Expression of GFPuv mutants with pAcFRS and MjtRNACUATyr variants 
MjtRNACUA
Tyr-Nap1 is a previously reported MjtRNACUA
Tyr variant with beneficial T-stem 
mutations.90 These mutations repaired a suboptimal interaction between archaeal tRNA and 
prokaryotic EF-Tu, and led to a significantly improved amber suppression efficiency.90 We 
investigated whether beneficial mutations of MjtRNACUA
Tyr-Nap1 and our evolved MjTyrRS 
variants can be combined to facilitate amber suppression. Since the T-stem of MjtRNACUA
Tyr-Nap1 
does not directly interact with MjTyrRS, we envisaged that it could still be efficiently recognized 
by pAcFRS variants. We compared the expression levels of GFPuv-Asn149UAG in E. coli 
GeneHogs in the presence of pAcFRS variants, MjtRNACUA
Tyr variants, and 1 mM pAcF. As 
shown in Figure 44, the combination of MjtRNACUA
Tyr-Nap1 with pAcFRS variants significantly 
enhanced the GFPuv expression level relative to MjtRNACUA
Tyr.     
We performed a large-scale purification of GFPuv-Asn149UAG in the presence of pAcFRS 
and MjtRNACUA
Tyr variants (Figure 45). The pAcFRS-8G/MjtRNACUA
Tyr-Nap1 pair resulted in 
the highest protein yield (~76.2 mg/L), which was approximately 2-fold higher than the pAcFRS-
8G/MjtRNACUA
Tyr pair (~33.9 mg/L) and 4-fold higher than the pAcFRS-wt/MjtRNACUA
Tyr pair 
(~17.9 mg/L). The previously reported mutant pAcFRS-D286R showed only minor improvement 
in incorporation efficiency (~22.7mg/L).  
4.2.5 Quantification of aminoacyl-tRNA synthetase expression level 
We examined the expression level of pAcFRS-wt and pAcFRS-8G by western blot. In order 
to quantify the two MjTyrRS variants in crude cell lysates, a 6× His-tag was fused to the C-
terminus of each protein during sub-cloning. As shown in Figure 46, we did not observe a 
difference between the two samples, which ruled out the possibility that the improvement in pAcF 
incorporation efficiency was due to a higher expression level of pAcFRS-8G.  
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4.2.6 Growth curves of cells containing the evolved aminoacyl-tRNA synthetase 
We evaluated the growth rate of E. coli cells harboring MjTyrRS variants. As shown in Figure 
47, pAcFRS-12B and BpaRS-8E grew at a similar rate to controls. Conversely, pAcFRS-8G and 
sTyrRS-5A displayed a relatively slower growth rate compared to controls. These results suggest 
the improvement in unAA incorporation was not due to faster growth rates of the evolved 
MjTyrRS variants.  
4.3 Summary and remarks 
In this chapter, we introduced a directed evolution approach to evolve aminoacyl-tRNA 
synthetase. By mutating key residues at the anticodon-binding interface, we identified MjTyrRS 
variants with notable enhancements in the unAA incorporation efficiency. The beneficial effects 
were likely due to an optimized recognition of the anticodon region in MjtRNACUA
Tyr by the 
evolved MjTyrRS variants. It was not caused by higher expression levels or lower toxicity of these 
synthetases. Significantly higher protein expression levels were achieved by the combination of 
evolved MjTyrRS variants and an optimized MjtRNACUA
Tyr. We also found that the optimal 
efficiencies of MjTyrRS-MjtRNACUA
Tyr pairs are unAA-specific. This strategy can potentially be 
applied to optimize the interaction between aaRSs and other nonsense codon suppressor tRNAs, 
such as quadruplet codon decoding tRNAs.  





Figure 38. Recognition of anticodon region of MjtRNAGUA
Tyr by MjTyrRS (PDB ID: 1J1U). 
  Reproduced with permission from “ACS Synthetic Biology. 2015, 4, 207. Copyright 2015 







Figure 39. Positive and negative selections to identify MjTyrRS mutants with enhanced unAA 





Figure 40. Characterization and validation of pAcFRS mutants. (A) Structure of p-acetyl-L-
phenylalanine (pAcF). (B) Sequences of pAcFRS variants. (C) GFPuv fluorescence assay of cells 
containing evolved pAcFRS derivatives and MjtRNACUA
Tyr in the presence or absence of 1 mM 
pAcF. Fluorescence intensity was normalized to cell density. The data shown was an average of 
duplicate measurements.  
Reproduced with permission from “ACS Synthetic Biology. 2015, 4, 207. Copyright 2015 






Figure 41. GFPuv fluorescence assay of cells containing MjTyrRS mutants. These MjTyrRS 
mutants share the same anticodon binding pocket with pAcFRS-8G. (A) Structure of Bpa, sTyr, 
pIodoF, and pAzF. (B) Fluorescence readings of cells containing MjTyrRS derivatives. The 
GFPuv expression was conducted in the presence of MjtRNACUA
Tyr, MjTyrRS derivatives and 
corresponding unAAs, respectively. The culture media was supplemented with 1 mM Bpa, 10 mM 
sTyr, 1 mM pIodoF, or 1 mM pAzF respectively.  Fluorescence intensity was normalized to cell 
density. The experiment was repeated multiple times and one representative set of data was 





Figure 42. Characterization and validation of BpaRS mutants. (A) Structure of p-benzoyl-L-
phenylalanine (Bpa). (B) Sequences of BpaRS variants. (C) GFPuv fluorescence assay of cells 
containing evolved BpaRS derivatives and MjtRNACUA
Tyr in the presence or absence of 1 mM Bpa. 
Fluorescence intensity was normalized to cell density. The data shown was an average of duplicate 
measurements.  
Reproduced with permission from “ACS Synthetic Biology. 2015, 4, 207. Copyright 2015 






Figure 43. Characterization and validation of sTyrRS mutants. (A) Structure of sulfotyrosine 
(sTyr). (B) Sequences of sTyrRS variants. (C) GFPuv fluorescence assay of cells containing 
evolved sTyrRS derivatives and MjtRNACUA
Tyr in the presence or absence of 2 mM sTyr. 
Fluorescence intensity was normalized to cell density. The data shown was an average of duplicate 
measurements.  
Reproduced with permission from “ACS Synthetic Biology. 2015, 4, 207. Copyright 2015 






Figure 44. GFPuv fluorescence assay of cells containing MjTyrRS and MjtRNACUA
Tyr variants.  
Reproduced with permission from “ACS Synthetic Biology. 2015, 4, 207. Copyright 2015 






Figure 45. Purification of GFPuv mutants in the presence of evolved pAcFRS and MjtRNACUA
Tyr 
variants. (A) SDS-PAGE of GFPuv mutants. GFPuv expression was conducted in the presence 
pAcFRS, MjtRNACUA
Tyr variants, and 1 mM pAcF. Lane 1, pAcFRS-8G + MjtRNACUA
Tyr; Lane 
2, pAcFRS-wt + MjtRNACUA
Tyr; Lane 3, pAcFRS-D286R + MjtRNACUA
Tyr; Lane 4, pAcFRS-8G 
+ MjtRNACUA
Tyr-Nap1. (B) Protein yields of each sample in (A). 1 mM of pAcF was supplemented 
in the culture media. 
Reproduced with permission from “ACS Synthetic Biology. 2015, 4, 207. Copyright 2015 






Figure 46. Western blot analysis of expression level of pAcFRS variants. Lane 1, protein maker; 
lane 2, pAcFRS-8G; lane 3, pAcFRS-8G; lane 4, pAcFRS-wt; lane 5, pAcFRS-wt. Protein 
expression was conducted in two biological repeats for pAcFRS-8G and pAcFRS-wt. Each 
sample was normalized to the same number of cells by OD600 measurement.  
Reproduced with permission from “ACS Synthetic Biology. 2015, 4, 207. Copyright 2015 





Figure 47. Growth curves of cells containing MjTyrRS variants. (A) E. coli GeneHogs containing 
pAcFRS variants. (B) E. coli GeneHogs containing BpaRS variants. (C) E. coli GeneHogs 
containing sTyrRS variants. The data shown was an average of triplicate measurements.  
Reproduced with permission from “ACS Synthetic Biology. 2015, 4, 207. Copyright 2015 






Experimental: Materials and methods 
5.1 General materials and methods 
5.1.1 General materials 
DNA manipulation. Restriction enzymes, Antarctic phosphatase (AP) were purchased from 
New England Biolabs (NEB). T4 DNA ligase was purchased from Thermo Fisher Scientific. KOD 
hot start DNA polymerase was purchased from EMD Millipore. All DNA oligonucleotides were 
purchased from Eurofins MWG operon or Sigma. Standard molecular biology techniques were 
used throughout.172 Site-directed mutagenesis, insertion and deletion of genes were carried out by 
overlapping PCR. 
E. coli strains. E. coli GeneHogs (Thermo Fisher Scientific) was used for routine cloning and 
DNA propagation for non-viral genes.  E. coli Max Efficiency Stbl-2 (Life Technologies) was used 
for manipulation of HIV-1 genes. E. coli C321.∆A.exp (Addgene) and C321.∆A (Addgene) were 
used for quadruplet decoding tRNA selection and evaluation. E. coli GeneHogs was used for 
MjTyrRS selection and evaluation.  
Medium and antibiotics. All solutions were prepared in deionized water which was further 
treated by Barnstead Nanopure ultrapure water purification system (Thermo Fischer Scientific Inc). 
All purchased chemicals were used without further purification. LB broth (1 L) was prepared by 
adding 25 g LB broth media (1% tryptone, 0.5% yeast extract, and 1% NaCl) into 1 L of ddH2O 
and autoclaved. SOC medium (1 L) was prepared by adding 32.6 g SOC broth media (2% tryptone, 
0.5% yeast extract, 2.5 mM KCl, 10 mM MgCl2, 20 mM MgSO4, 20 mM glucose) in 1 L of ddH2O 
and autoclaved. LB agar (1 L) was prepared by adding 25 g LB broth media and 15 g agar into 1 
L of ddH2O and autoclaved. Antibiotics were added where appropriate to following final 
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concentration: ampicillin, 100 μg/mL; kanamycin, 50 μg/mL; tetracycline, 12.5 μg/mL; 
chloramphenicol 34 μg/mL or other concentrations for positive selections. 
Unnatural amino acids (unAAs). The unnatural amino acids (unAAs), p-azido-L-
phenylalanine (pAzF), p-iodo-L-phenylalanine (pIodoF), p-benzyol-L-phenylalanine (Bpa), and 
Nε-(tert-butoxycarbonyl)-L-lysine (BocK) were purchased from Bachem. p-acetyl-L-
phenylalanine (pAcF),45 sulfotyrosine (sTyr),173 o-nitrobenzyl-oxycarbonyl-Nε-L-lysine 
(ONBK),125 o-nitrobenzyl-tyrosine (ONBY),49 and 3’-azibutyl-N-carbamoyl-lysine (AbK)164  
were synthesized following previously reported methods.  
Protein purification and western blot reagents. Ni Sepharose 6 Fast Flow resin (GE 
Healthcare) was used for purification of His-tagged fusion proteins. Glutathione Sepharose 4B 
resin (GE Healthcare) was used for purification of GST-tagged fusion proteins. BugBuster protein 
extraction reagent (EMD Millipore) was used for small-scale cell lysis and protein purification. 
6x-His Tag monoclonal antibody (mouse) from Thermo Fisher Scientific was used for probing 
His-tagged fusion proteins in western blot. StrepTactin-HRP conjugate (Bio-Rad) was used to 
detect and quantify proteins fused with Strep-tag II in western blot. Goat-anti-mouse IgG (H+L)-
HRP conjugate (Bio-Rad) was used as a secondary antibody for detecting mouse IgG primary 
antibody. 
5.1.2 General methods 
PCR. All PCR reactions were performed following standard protocols being described 
before.172 A typical PCR reaction solution(25 μL) contained 2.5 μL of 10X buffer for KOD Hot 
Start DNA polymerase, 1.5 μL of MgSO4 (25 mM), 2.5 μL of dNTPs (2 mM each), 0.75 μL of 
primer mixture (10 μM each), 0.5 μL of DNA template (10-20 ng/μL), 0.5 μL of KOD Hot Start 
DNA polymerase, and 16.75 μL of ddH2O. For library construction, a larger scale (100-200 μL) 
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of PCR reaction was performed to obtain higher yields of amplification products. A typical 3-step 
PCR reaction was conducted under following conditions: a hot start at 95 °C for 2 min, and then 
35 cycles of 95 °C for 20 s (denature), 56 °C for 15 s (annealing), and 70 °C for certain time 
(extension), and then a final extension at 70 °C for 3 min.  
The reaction solution for overlapping PCR was prepared in a similar way as described above. 
But the primer mixture was omitted from the initial solution and DNA fragments with overlapping 
overhangs were used as the template. The PCR reaction was conducted under following conditions: 
95 °C for 2 min, and then 10 cycles of 95 °C for 20 s, 50 °C for 15s, and 70 °C for certain time, 
and then paused at 4 °C. After the addition of the primer mixture, the PCR reaction was resumed, 
and conducted under following conditions: 30 cycles of 95 °C for 20 s, 56 °C for 15 s, and 70 °C 
for certain time, and then a final extension at 70 °C for 3 min.  
Restriction enzyme digestion. Generally, the vector and insert were digested with the same 
restriction enzymes to create blunt ends or compatible sticky ends for ligation.  A typical digestion 
reaction (40 μL) contained 10 μL of DNA (~100 ng/μL), 4 μL of 10X digestion buffer, 1 μL of 
each restriction enzyme, and proper amount of ddH2O. The reaction was incubated at suggested 
temperature (normally 37 °C) for 3 h.  
Agarose gel electrophoresis. Agarose gels were commonly prepared at concentrations of 0.8% 
to 2% (w/v) in 1X TAE buffer based on the size of DNA fragments needed to be isolated. Ethidium 
bromide (0.5 μg/mL) was added into the agarose solution to allow for visualization of DNA 
fragments under UV light. To analyze or purify DNA fragments (e.g., plasmid after restriction 
enzyme digestion), the samples were mixed with 6X loading dye and then loaded into a freshly 
poured agarose gel alongside a DNA ladder. Then the gel was run in 1X TAE buffer at 100 V for 
45-60 min. The size of DNA fragments was determined by comparison to the DNA ladder. The 
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gel bands containing desired DNA fragments were carefully cut out using razor blades and directly 
used for gel extraction.   
DNA gel extraction. Zymoclean DNA Gel Extraction kit was used to extract DNA from 
excised agarose gel slice. In a 1.5 mL Eppendorf tube, one volume of gel slice was mixed with 
three volumes of agarose dissolving buffer (ADB). The resulting suspension was incubated at 
52 °C until the gel was fully dissolved.  The dissolved DNA-gel solution was loaded onto a Zymo-
spin column, extracted, and washed following manufacturer’s instructions. The purified DNA was 
eluted in 10-20 μL ddH2O and stored at 4 °C.  
Ligation. To ligate the digested insert into a vector (recipient plasmid), a standard ligation 
reaction was performed.  In general, a vector + insert ligation reaction (5 μL) contained 50 ng of 
vector, insert (the molar ratio of insert: vector was 3:1), 0.5 μL of 10X T4 ligation buffer, 0.25 μL 
of T4 ligase, and proper amount of ddH2O. A vector only control was used to determine the 
“background” level of self-ligation of the vector. For a regular cloning, the ligation reaction was 
incubated at room temperature for 1 h before transformation. For the construction of an aaRS or 
tRNA library, the ligation reaction was performed at 14 °C for 16 h in a larger scale (1 μg of vector 
+ appropriate amount of insert).  
Sequence and ligation independent cloning (SLIC cloning). Unlike traditional ligation 
dependent cloning, SLIC is not constrained by DNA sequence contents. This approach relies on 
T4 DNA polymerase’s exonuclease activity to create homologous overhangs in both vector and 
insert, which allows for subsequent annealing and assembly. A SLIC cloning reaction (20 μL) 
containing 150 ng of linearized plasmid DNA, insert (with a 2:1 molar ratio of insert: vector), 2 
μL Buffer 2.1 (NEB), 1 μL T4 DNA polymerase (1:6 dilution in Buffer 2.1), and ddH2O, was 
prepared on ice. Then the reaction mixture was incubated at 22 °C for 30 min (3’ to 5’ exonuclease 
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digestion), 75 °C for 15 min (heat inactivation of T4 DNA polymerase), and 37 °C for 20 min 
(annealing). Then 2 μL of the reaction mixture was transformed into GeneHogs chemical 
competent cells to obtain single colonies.  
Preparation of chemical competent cells. An E. coli strain of interest was streaked on LB 
agar containing appropriate antibiotics (or no antibiotics) to obtain single colonies. Then a single 
colony was cultured in 5 mL LB at 37 °C (GeneHogs and C321.ΔA.exp) or 30 °C (C321.ΔA and 
Stbl2) overnight with shaking. 1 mL of overnight culture was sub-cultured in 100 mL of fresh LB 
medium at 30 °C with shaking until reaching OD600 of 0.4 to 0.6. The cells were harvested and 
centrifuged at 5,000g and 4 °C for 10 min. The cells were resuspended in 1 mL of pre-chilled 
CCMB solution on ice and centrifuged again. The supernatant was carefully removed and the cells 
were resuspended in 4 mL of pre-chilled CCMB solution on ice. The cell suspension was aliquoted 
into 50 μL portions in 1.5 mL Eppendorf tubes and stored at -80 °C.  
Transformation of chemical competent cells. An aliquot of chemical competent cells (50 
μL) was thawed on ice, followed by addition of 10-100 ng of DNA sample, such as, ligation 
products, SLIC cloning products, and plasmids. The cells were incubated on ice for 15-30 min, 
followed a heat shock at 42 °C for 25-30 s. The cells were immediately moved back to ice bath 
and incubated for another 2 min. Then 450 μL of LB or SOC medium was added into each sample 
and the cells were allowed to recover at 37 °C (GeneHogs and C321.ΔA.exp) for 1 h or at 30 °C 
(C321.ΔA and Stbl2) for 1.5 h. 100 μL of recovered cells were plated on LB agar containing 
appropriate antibiotics and incubated overnight to obtain single colonies. 
Preparation of electrocompetent cells. The E. coli strain of interest was cultured in 1 L of 
LB medium following the same protocol when preparing chemical competent cells. When OD600 
of 0.6-1.0 was reached, the cells were harvested and centrifuged at 5,000g and 4 °C for 10 min. 
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The cells were resuspended in 100-200 mL of pre-chilled autoclaved ddH2O on ice, and 
centrifuged at 5,200g and 4 °C for 10 min. After carefully removing the supernatant, the cells were 
resuspended in 100-200 mL of pre-chilled autoclaved 10% glycerol solution on ice, and 
centrifuged at 5,200g and 4 °C for 10 min. The washing step was repeated twice with glycerol 
solution. Each volume of cell pellet was subsequently resuspended in half-volume of 10% glycerol 
solution on ice, aliquoted into 60 μL portions into 1.5 mL Eppendorf tubes and used freshly for 
electroporation. 
Electroporation of electrocompetent cells. In this study, electroporation was used for the 
construction and selection of a tRNA or aaRS library. Briefly, 2 μL of concentrated ligation 
products or plasmid DNA (100-250 ng/μL) was added into an aliquot of freshly prepared 
electrocompetent cells on ice and mixed by gently stirring. The cell suspension was transferred 
into a pre-chilled electroporation cuvette on ice. The cells were electroporated at 2500 V 
(Eppendorf Electroporator 2510) and immediately resuspended in 1 mL of pre-warmed SOC 
medium.  The cuvette was rinsed with an additional 1 mL of SOC medium. The combined cell 
suspension was transferred into a pre-warmed 50 mL Erlenmeyer flask and recovered at 37 °C for 
1 h with shaking. Then the cells were transferred into pre-warmed LB broth with appropriate 
antibiotics and cultivated overnight at 37 °C with shaking. After 18 h of cultivation, 2 tubes of 
glycerol stocks were made by mixing 0.75 mL of cell culture with 0.5 mL of 50% glycerol solution 
in a 2 mL cryo-tube and stored at -80 °C.  Certain number of cells (>4.6 × library size) were plated 
on LB agar containing appropriate antibiotics for the selection.  
Transfection. Transfection was commonly used to introduce DNA or RNA into mammalian 
cells. Briefly, the cells were seeded in a 6-well plate to be 50-70% confluent at transfection.  Before 
transfection, the cell culture medium was replaced with 1 mL of fresh DMEM medium without 
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FBS. In one 1.5 mL Eppendorf tube, 1 μg of each plasmid DNA was diluted in 500 μL DMEM. In 
another tube, 10 μL of lipofectamine 2000 transfection reagent was diluted in 500 μL DMEM. The 
diluted DNA was added into diluted lipofectamine solution. The DNA-lipid complex was 
incubated at room temperature for 20 min before being added to cells. 48 h after transfection, the 
cells were imaged and virus-containing cell culture was collected for future analysis.  
5.2 Experimental for Chapter 2 
5.2.1 Plasmid construction 
pcDNA3.1-tRNACUA. The amber suppressor tRNACUA was derived from Bacillus 
stearothermophilus tRNATyr.  The G35 of the tRNATyr was mutated to C to generate a CUA 
anticodon.  The tRNACUA gene lacking 3’-CCA but with a 3’-TTTTTCT sequence was PCR 
amplified.  A human U6 promoter was PCR amplified from pCMV-pylRSNBK-1174 and added in 
front of the tRNACUA gene by overlapping PCR.  The U6-tRNACUA gene cassette was PCR 
amplified and inserted into pcDNA3.1/hygro+ (Life Technologies) in front of the CMV promoter 
to afford pcDNA3.1-tRNACUA. 
pAzFRS.  The AzFRS-encoding gene was PCR amplified from plasmid pSWAN-pAzpaRS175 
and inserted into pcDNA3.1-tRNACUA behind the non-regulated CMV promoter to afford plasmid 
pAzFRS. 
pAcFRS.  The AcFRS-encoding gene was PCR amplified from plasmid pSWAN-pApaRS175 




pIodoFRS.  The IodoFRS-encoding gene was PCR amplified from plasmid pSWAN-
pIpaRS175 and inserted into pcDNA3.1-tRNACUA behind the non-regulated CMV promoter to 
afford plasmid pAzFRS. 
pEGFP.  The EGFP-encoding gene containing an amber nonsense codon at a permissive site 
(Tyr40TAG) was inserted into pcDNA3.1-tRNACUA behind the non-regulated CMV promoter to 
afford plasmid pEGFP. 
pSUMA variants. HIV-1 clone, pSUMA.c/2821(referred to as pSUMA-wt), was obtained 
though the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH, from Dr. John Kappes 
and Dr. Chistina Ochsenbauer. Overlapping PCR was used to introduce amber mutations onto the 
HIV-1 genome encoded by pSUMA.  
pNL4-3 variants. HIV-1 clone, pNL4-3(referred to as pNL43-wt), was obtained though the 
NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr. Malcolm Martin. Plasmids 
HIV-1-iGFP and HIV-1-NL-GI were generous gifts from Dr. Benjamin K. Chen.176,177 To facilitate 
the insertion of foreign genes into HIV-1 genome, two unique restriction enzyme cutting sites, 
ClaI and XmaI, were introduced into pNL43-wt to yield pNL43-ClaI-XmaI. The two cutting sites 
were installed between env and nef genes by overlapping PCR using primers SUMA.Env.Nef SeqF, 
NL43-Cla1-R,  NL43-Xma1-F, and NL43-Nef-R3. The AzFRS-encoding gene was PCR amplified 
using primers AzF-ClaI and AzF-XmaI and inserted into pNL43-ClaI-XmaI between ClaI and 
XmaI sites to afford pNL43-AzFRS. EGFP and BocKRS-encoding genes were inserted at the same 
locus to give pNL43-EGFP and pNL43-BockRS respectively. The U6-tRNACUA cassette was PCR 
amplified and inserted into ClaI or XmaI site of pNL43-AzFRS to yield four different constructs, 
pNL43-AzFRS-tRNA-X (X=1, 2, 3, and 4). Amber mutations at position Trp36 of p17 and 
position Tyr59 of HIV-1 protease were introduced into pNL43-AzFRS-tRNA-2 using overlapping 
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PCR. All of the five genomic UAG codons were replaced with UAA codons in pNL43-wt to afford 
pNL43-All-UAA. The modifications on pNL43-Trp36-AzFRS-tRNA-2 and pNL43-Tyr59-
AzFRS-tRNA-2 were transplanted into pNL43-All-UAA to generate amber free versions of HIV-
1 variants. CMV promoter were inserted before AzFRS-encoding gene to give pNL43-Trp36-
CMV-AzFRS-tRNA-2 and pNL43-Tyr59-CMV-AzFRS-tRNA-2.  


















Mut4-R1  TTTCCTGCGTCAGCCTATGCTTGCTGTGCTTTTTTCTTAC 






Mut5-R1  AATCCCTAGATTATCCATCTTTTATAAATTTCTCCTAC 




Mut6-R1  GGAACTGACTAATATGCATCACCCACATCTAG 




Mut7-R1  CACCTCTACAGATGTTCTCTCAGTTCCTC  









Mut9-R1  CAGGGTTAACTG CTATCGTTCTAGCTCCCTGCTTG   




Mut10-R-BstEII  ATTTCTATGGTTACCTGATCCTATTGTCTTACTTTGATAAAAC 
SUMA-CA-K359 
SUMA-Hpa1-F1 CAGGGAGCTAGAACGATTCGCAGTTAACCCT 





























































5.2.2 Transfection and generation of HIV-1 
293T cells were grown in 2 mL DMEM medium containing 10% FBS and 2 mM L-glutamine 
at 37 °C in 6-well flat bottom plates in a humidified atmosphere of 5% CO2. When 60-70% 
confluency was reached, cells were transfected with 1μg of appropriate plasmid(s) using 
Lipofectamine 2000 (Life Technologies) following manufacturer's instructions. 6 h post-
transfection, the culture medium containing transfection reagent was carefully removed and 
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replaced with 2 mL fresh medium with or without unAA. A final concentration of 1 mM pAzF, 1 
mM pIodoF, 1 mM pAcF, 0.4 mM ONBY, or 1 mM ONBK was added into the medium for 
corresponding studies. After 48 h of cultivation, the supernatant was collected separately from 
each well. The FBS concentration in the harvested culture medium was adjusted to 20%. The 
culture medium was filtered through a 0.45-μm filter. Viral load of the filtered culture medium 
was determined by p24-assay or qRT-PCR. Then the culture medium was directly used for 
infection assay or stored at -150 °C for later analysis.   
5.2.3 Virus ultracentrifugation  
293T cells in T175 flasks were transfected with appropriate plasmids (60 μg) using 
Lipofectamine 2000 (120 μL). After 48 h of cultivation, cell culture medium was collected from 
each flask separately and filtered through a 0.45-μm filter. The filtrate (35 mL) from each flask 
was centrifuged at 25,000 rpm in Optima L-100X ultracentrifuge (Beckman Coulter) at 4 °C for 
90 min. The virus pellet was resuspended in 1 mL fresh medium and aliquoted into 200 μL portions 
in sterile screw-cap vials and stored at -150 °C.   
5.2.4 Quantification of viral load 
p24 assay. The presence and level of p24 (HIV-1 capsid protein) in collected culture medium 
was measured with Retroteck HIV-1 p24 Antigen ELISA 2.0 kit (ZeptoMetrix Corporation) 
following manufacturer’s instructions. Briefly, 200 μL viral-containing culture medium, the 
positive control (125 pg/mL p24) and the negative control were added separately into micro-plate 
wells coated with anti-p24 monoclonal antibody and incubated at 37 °C for 1.5 h. Then the wells 
were washed and incubated with antibody-HP conjugate at 37 °C for 1 h. After multiple washes, 
HRP-substrate was added into the wells for color development. The reactions were stopped by the 
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addition of 1 M H2SO4 and absorbance at 450 nm were examined. The amount of p24 was obtained 
by interpolation from a point-to-point plot or from a linear regression analysis of the standard curve.  
qRT-PCR. Viral RNAs were extracted from collected culture medium using QIAamp Viral 
RNA Mini kit (Qiagen). The viral load was determined by qRT-PCR using C1000 Thermo Cycler 
and CFX96 Real-time system (Bio-Rad) with Taqman Fast Virus 1-Step Master Mix (Life 
Technologies), using primers V1: 5’-GCCTCAATAAAGCTTGCCTTGA-3’, V2: 5’-
GGGCGCCACTGCTAGAGA-3’, and probe V3: 5’-/FAM/CCAGAGTCACACAACAG 
ACGGGCACA/BHQ_1/-3’. 
5.2.5 Infection assay 
Qualitative infection assay. The infectivity of HIV-1 variants was evaluated using TZM-bl 
cells and X-gal staining (Genlantis). Briefly, a mixture of virus-containing culture medium, 10% 
DMEM growth media and DEAE-dextran (final concentration of 40 mg/mL), were added into 
each well of 6-well flat bottom plates that contained TZM-bl cells. After 48 h of cultivation at 
37 °C in a humidified atmosphere of 5% CO2, TZM-bl cells were washed, fixed, and stained using 
X-gal solution for 2 h at 37 °C. Infectivity was evaluated by counting X-gal-positive cells under a 
light microscope.  
Tissue Culture Infectious Dose 50 (TCID50). Infectious titers of HIV-1 variants were 
quantified by standard tissue culture infectious dose 50 (TCID50) method using X-gal staining 
assay (as mentioned above). Briefly, 4-fold serial dilutions of viruses were performed in 
quadruplicate in 96-well flat bottom plates and applied for X-gal staining assay. The TCID50 values 
were calculated by Spearman-Karber formula according to the negative end-point and dilution 
factors. The TZM-bl cell-only sample and the wild-type HIV-1 virus were included as negative 
and positive controls respectively in all TCID50 measurements.  
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Multicycle infection assay. Concentrated viruses from ultracentrifugation (200 μL) were 
added to T25 flasks containing 1 × 106 Sup-T1 cells. After 24 h of cultivation, cells were collected 
by centrifugation and the supernatants containing unadsorbed viruses were discarded. The cell 
pellets were resuspended in 5 mL fresh medium and was centrifuged again to remove residual free 
viruses. The cell pellets were resuspended in 5 mL culture with or without 1 mM pAzF and 
cultivated at 37 °C in a humidified atmosphere of 5% CO2. The status of cells was monitored 
everyday by a light microscope. After 2 weeks of cultivation, viruses were collected by 
ultracentrifugation and TCID50 values were measured.    
5.2.6 Fluorescence spectroscopy and cell imaging 
The fluorescent images and bright-field images were obtained by a Nikon Eclipse TE3000 
microscope and an EVOS FL Auto Imaging System with DIC, respectively. The samples were 
excited at 488 nm to acquire EGFP fluorescence images at 530/25 nm.  
5.2.7 Analysis of AzFRS transcription using quantitative PCR 
48 h post-transfection, the total RNA was extracted from transfected 293T cells using RNeasy 
Plus Mini Kit (Qiagen). The quantity and purity of RNA samples were determined by NanoDrop 
2000 (Thermo Scientific). The cDNA was synthesized using an oligo-dT primer (IDT) and 
Superscript III reverse transcriptase (Life Technologies) on C1000 Thermo Cycler (Bio-Rad). The 
qPCR was conducted on the CFX96 Real-Time detection system (Bio-Rad) using a hot start (95 °C 
for 5 min), and 40 amplification cycles (95 °C for 15s, 60 °C for 30s). For amplification and 
detection of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) control, primers Q1: 5’-
ACATCATCCCTGCCTCTACT-3’ and Q2: 5’-TCAGGTCCACCACTGACA-3’, and probe Q3: 
5’-/56-FAM/CAAGGTCAT/ZEN/CCCTGAGCTGAACGG/3IABkFQ/-3’ were used. For 
amplification and detection of AzFRS gene, primers Q4: 5’-GCATCAGAATCAGGTGTTTGG-3’ 
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and Q5: 5’-TGGTAGAATTTGTACGGGCTG-3’, and probe Q6: 5’-/56-
FAM/TGCTTTAGT/ZEN/GATCAGCGGAACGGT/3IABkFQ/-3’ were used.  
5.2.8 Viral transcription and provirus detection using RNAscope and DNAscope in situ 
hybridization 
Viral RNA and DNA were detected using single-copy sensitivity DNAscope and RNAscope 
in situ hybridization (ISH) techniques.178 Briefly, after 72 h of cultivation  with or without pAzF, 
Sup-T1 cells were collected and centrifuged, spotted on glass-slide, and fixed with 4% PFA for 1 
h. HIV-1 viral RNA was detected with V-HIV Clade B antisense probes and RNAscope 2.0 HD 
rad reagent kit (Advanced Cell Diagnostics, CA). HIV-1 viral DNA was detected with V-HIV 
Clade B sense probes and RNAscope 2.0 HD red reagent (Advanced Cell Diagnostics, CA). All 
experiments were conducted according to manufacturer’s instructions.  
5.2.9 Amplification and sequencing for aaRS-tRNACUA insertion 
Cells infected with wild-type pNL4-3 virus, the pNL43-Trp36-AzFRS-tRNA-2 variant, or the 
pNL43-Tyr59-AzFRS-tRNA-2 variant were collected from Sup-T1 cells after 2 weeks of 
cultivation in the presence of pAzF. Viral RNA was extracted from cell culture using QIAamp 
Viral RNA Mini kit (Qiagen). RNA quality was verified using NanoDrop 2000 (Thermo 
Scientific). The cDNA of extracted RNA was synthesized by reverse transcription using 
Superscript III reagents (Life Technologies). The mixture of viral RNA and a gene-specific 
antisense primer (5’-AAGATCTACAGCTGCCTT-3’) was heated at 65 °C for 5 min and then 
incubated on ice for 2 min. A master mix consisting of following reagents was then added: 5× 
First-Strand buffer, dithiothreitol, RNaseOUT recombinant RNase Inhibitor (40 units/μL), 
SuperScriptIII RT (200 units/μL), and RNase free water. The mixture was incubated at 50 °C for 
60 min, 70 °C for 15 min, followed by the addition of 1 μL RNase H (5U/μL) and incubation at 
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37 °C for additional 20 min.  The cDNA was stored at -20 °C for future analysis. PCR amplification 
of AzFRS-tRNACUA insertion was performed using High Fidelity Platinum Taq polymerase 
(Invitrogen) in a 20 μL of reaction with forward primer 5’-TTATAGAAGTATTACAAG- 
CAGCTTATAG-3’ and reverse primer 5’- AAGATCTACAGCTGCCTT-3’ under the following 
conditions: 94 °C for 5 min, 36 cycles of 94 °C for 30 s, 53 °C for 30 s, and 68 °C for 2 min, and 
a final extension at 68 °C for 5 min. The amplicons of full-length insertion were sequenced at 
Sequetech (Mountain View, CA) using the Sanger method.  
5.2.10 Protein expression and purification 
293T cells were grown in T75 flasks with DMEM medium containing 10% FBS, and 2 mM 
L-glutamine at 37 °C in a humidified atmosphere of 5% CO2. When 60-70% confluency was 
reached, 293T cells were transfected with 12 μg of pEGFP-40TAG plasmid and 12 μg of pAzFRS 
plasmid with 36 μL Lipofectamine 2000 according to manufacturer’s instructions. 6 h post-
transfection, the culture medium was replaced with 12 mL fresh medium containing 1 mM pAzF. 
Cells were cultivated for additional 36 h before being washed with DPBS, lysed with RIPA buffer 
(Thermo Scientific), and partially purified using Ni-NTA resin (GE Healthcare).  
5.2.11 LC/MS/MS 
The corresponding protein band of EGFP-40pAzF was cut from SDS-PAGE and in-gel 
digested with trypsin (in 50 mM ammonium bicarbonate, pH 8.0) overnight at 37 °C. The resulting 
peptide fragment were extracted with 0.1% formic acid/75% acetonitrile, and then subjected to 
LC/MS/MS analysis using a Waters Q-TOF Ultima. Database searches were performed on an in-
house Mascot server (Matrix Science Ltd., London, UK). For pAzF substitution site mapping on 
EGFP, pAzF substitution for tyrosine was included as a variable modification.  
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5.3 Experimental for Chapter 3 
5.3.1 Plasmid construction 
pBK-tRNANCUAPyl-N11 library. Procedures for library construction were adapted from a 
previously reported method.179 The tRNA mutants with complete randomization at 11 selected 
positions in ASL were obtained by overlapping PCR using pBK-mmPylT as the template.125 The 
resulting PCR product containing lpp promoter-RNA mutants-rrnC terminator was digested with 
NcoI and XhoI and inserted into the same sites of pBK vector to generated pBK-tRNANNCUA
Pyl-
N11 library. The quality of this library was confirmed by DNA sequencing.  
pBK-tRNACUAPyl-N10 library. The tRNACUA
Pyl-N10 library was constructed following the 
same protocol described above. Briefly, the tRNA mutants with complete randomization at 10 
selected positions in ASL was inserted into NcoI and XhoI sites of pBK-vector to afford pBK-
tRNACUA
Pyl-N10 library. The quality of this library was confirmed by DNA sequencing. 
pBK-BocKRS. Plasmid pBK-BocKRS was constructed by inserting BockRS-encoding gene 
behind the constitutive glnS promoter (PglnS) on pBK vector.
180 
pREP-BocKRS-UAGN (positive selection reporter). This reporter was constructed by 
modifying plasmid pRep-Cm12b.90 Briefly, the UAG codon at position 98 in the chloramphenicol 
acetyltransferase-encoding gene on pRep-Cm12b was changed to UAGN (N= A, U, G, or C) by 
site-directed mutagenesis. The resulting plasmid, pRepCM12b-UAGN, was digested with XbaI 
and ligated to a DNA fragment encoding PglnS-BocKRS cassette, which was amplified from pBK-
BockRS, to yield plasmid pREP-BockRS-UAGN. Individual plasmids with different quadruplet 
codons of interest, pREP-BockRS-UAGA, pREP-BockRS-UAGU, pREP-BockRS-UAGG, and 
pREP-BockRS-UAGC were isolated from single E. coli colonies and verified by DNA sequencing. 
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pGFPuv-UAGN (GFPuv reporter). Four different pGFPuv-UAGN(N=A, U, G, or C) 
reporters were constructed by inserting a DNA fragment encoding GFPuv-Asn149UAGN into 
NdeI and SacI sites of plasmid pLei-GFPuv-Asn149UAG90 to replace the original GFPuv reporter.    
pGFPuv-NCUA-wt (N= A, G, U, or C). A single insertion 33.5N (N= A, G, U, or C) was 
introduced into tRNACUA
Pyl-wt by overlapping PCR to yield tRNANCUA
Pyl-wt. The encoding genes 
for tRNANCUA
Pyl-wt were inserted between SpeI and PstI sites of pGFPuv-UAGN to yield pGFPuv-
NCUA-wt.  
pGFPuv-NCUA-X (N= A, G, U, or C; X= hit number). The encoding genes for tRNA hits 
were inserted between SpeI and PstI sites of corresponding pGFPuv-UAGN reporters by SLIC-
cloning to give pGFPuv-NCUA-X variants.  
pGFPuv-UAGN-BocKRS (N= A, G, U, or C).  The pGFPuv-UAGN-BocKRS reporters 
were generated by deleting the original tRNA fragment and inserting a DNA fragment encoding 
PglnS-BocKRS cassette, which was amplified from pBK-BockRS, into SpeI and PstI sites of 
pGFPuv-NCUA-wt by SLIC-cloning. 
pGFPuv-UAG-BocKRS. The pGFPuv-UAG-BocKRS reporter was constructed by deleting 
the original tRNA fragment and inserting a DNA fragment encoding PglnS-BocKRS cassette, which 
was amplified from pBK-BockRS, into SpeI and PstI sites of pLei-GFPuv-Asn149UAG90 by 
SLIC-cloning. 
































pLei-GFP-F-NdeI  GAGAAATTACATATGAGTAAAG 






















5.3.2 Positive selection 
The library plasmids were transformed into E. coli C321.∆A.exp or C321.∆A 
electrocompetent cells containing plasmid pREP-BocKRS-UAGN (N=A, G, U, or C). 
Transformants were cultivated in LB media containing kanamycin and tetracycline. After 12 h of 
cultivation, cells were harvested. Based on calculation, a certain number of cells (>4.6 × the size 
of the library) were plated on LB agar containing kanamycin (50 μg/mL), tetracycline (12.5 
μg/mL), BocK (5 mM), and chloramphenicol (concentration ranging from 34 μg/mL to 75 μg/mL). 
The selection plates were incubated at 37 °C (C321.∆A.exp) or 30 °C(C321.∆A) for 48 h.  
5.3.3 Hit verification 
Selected numbers of single colonies were further screened by replication onto LB agar plates 
with varying concentrations (50, 75, or 100 μg/mL) of chloramphenicol in the presence or absence 
of 5 mM BocK. Only the one that grew in the presence of BocK but did not grow in the absence 
of BocK were further characterized. 
5.3.4 Fluorescence analysis of bacterial culture 
E. coli C321.∆A containing plasmid pBK-BocKRS and a pGFPuv-NCUA variant (wt or tRNA 
hits) was cultured in 1 mL LB media containing ampicillin, kanamycin, and chloramphenicol at 
30 °C. After 18 h of cultivation, 50 μL culture was sub-cultured in 1 mL fresh LB medium 
containing ampicillin, kanamycin, chloramphenicol, IPTG (0.1 mM), and 5 mM BocK (or 5 mM 
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Lys, or none). After addition 16 h of cultivation at 30 °C, 1 mL of culture was collected, washed, 
and resuspended in 1 mL of potassium phosphate buffer (50 mM, pH 7.4). The processed cells 
were directly used for fluorescence and cell density measurements using a Synergy H1 Hybrid 
plate reader (BioTek Instruments). The fluorescence of GFPuv was monitored at λEx =390 nm and 
λEm =510 nm. The cell density was measured by absorbance at 600 nm. The fluorescence intensity 
was normalized to cell density for comparison of different samples. The incorporation of AbK and 
ONBK was conducted using the same protocol described above with previously reported PylRS 
variants. The cross test among different UAGN codons were conducted using a combination of 
pBK-tRNA-hit and pGFPuv-UAG(N)-BocKRS. Reported data was the average of three 
measurements with standard deviations. 
5.3.5 Protein expression and purification 
E. coli C321.∆A containing plasmid pBK-BocKRS and a pGFPuv-NCUA-X variant was 
cultured in 5 mL LB media containing kanamycin, chloramphenicol at 30 °C. After 18 h of 
cultivation, 0.5 mL culture was sub-cultured in 50 mL medium. The protein expression was 
induced at OD600 of 0.6 by addition of IPTG (0.5 mM) and BocK (5 mM). Cells were collected by 
centrifugation at 5,000 g and 4 °C for 15 min. Harvested cells were resuspended in lysis buffer 
containing potassium phosphate (20 mM, pH 7.4), NaCl (150 mM) and imidazole (10 mM). Then 
cells were lysed by sonication. Cell debris was removed by centrifugation (21,000 g, 4 °C, 30 min). 
The cell-free lysate was applied to Ni Sepharose 6 Fast Flow resin (GE Healthcare). Protein 
purification was conducted by following manufacturer’s instructions. Protein concentrations were 
determined by Bradford assay (Bio-Rad). Purified protein was isolated by SDS-PAGE and 
digested with trypsin prior to MS analysis.   
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5.4 Experimental for Chapter 4 
5.4.1 Plasmid construction 
pBK-pAcFRS-library. Residues Phe261, His283, Met285 and Asp286 in pAcFRS were 
mutated to NNK (N=A, G, U, or C; K=U, G) by overlapping PCR using pAcFRS-wt45 as template. 
The PCR products were digested with NdeI and PstI and then ligated into NdeI and PstI sites of 
pBK181 vector to give a pAcFRS library.  
pBK-BpaRS-library. Residues Phe261, His283, Met285 and Asp286 in BpaRS were mutated 
to NNK (N=A, G, U, or C; K=U, G) by overlapping PCR using BpaRS-wt11 as template. The PCR 
products were digested with NdeI and PstI and then ligated into NdeI and PstI sites of pBK181 
vector to give a BpaRS library.  
pBK-sTyrRS-library. Residues Phe261, His283, Met285 and Asp286 in sTyrRS were 
mutated to NNK (N=A, G, U, or C; K=U, G) by overlapping PCR using sTyrRS-wt47 as template. 
The PCR products were digested with NdeI and PstI and then ligated into NdeI and PstI sites of 
pBK181 vector to give a sTyrRS library.  
The following primers were used in the evolution of MjTyrRS variants: 
pBK-MjTyrRS-library 
pBK-TyrRS-NdeI-F1 TTGAGGAATCCCATATGGACGA 
TyrRS-Lib1-R1 CAATTCCTTATTTTTAAATAA  
TyrRS-Lib1-F2 TTATTTAAAAATAAGGAATTGNNKCCANNKNNKTTAAAAAATGCTGTAGCTGAAG  
TyrRS-Lib1-R2 GCGAACGCCTTATCCGGCCTG  






TyrRS-Lib1-R1 CAATTCCTTATTTTTAAATAA  
pBK-wtAcF-D286R-F2 AAAAATAAGGAATTGCATCCAATGCGCTTAAAAAATGCTG  
TyrRS-Lib1-R2 GCGAACGCCTTATCCGGCCTG  
pBK-MjTyrRS-8G variants 
pBK-TyrRS-NdeI-F1 TTGAGGAATCCCATATGGACGA 
8G-R1 CTCCATCCCTCCAACAGC  
8G-F2 GCTGTTGGAGGGATGGAG 
TyrRS-Lib1-R2 GCGAACGCCTTATCCGGCCTG  
 
5.4.2 Positive selection 
The library DNAs were transformed into E. coli GeneHogs electrocompetent cells containing 
plasmid pREP181 that harbors MjtRNACUA
Tyr and a chloramphenicol acetyltransferase-encoding 
gene with an amber mutation at position Asp112. Transformants were cultivated in LB media 
containing kanamycin and tetracycline. After 12 h of cultivation, cells were harvested. Based on 
calculation, a certain number of cells (>4.6 × the size of the library) were plated on LB agar 
containing kanamycin, tetracycline, unAA (e.g., 1 mM pAcF), and chloramphenicol 
(concentration ranging from 50 μg/mL to 250 μg/mL). The selection plates were incubated at 37 °C 
for 24 h. Survived cells were pooled and library plasmids were isolated by DNA gel electrophoresis.  
5.4.3 Negative selection 
E. coli GeneHogs was cotransformed with plasmid pNEG181 (containing MjtRNACUA
Tyr and 
a barnase-encoding gene with two amber mutations at position Gln2 and Asp44) and library 
plasmids isolated from the positive selection. Transformants were plated on LB agar containing 
ampicillin, kanamycin, and 0.2% L-arabinose. The selection plates were incubated at 37 °C for 12 




5.4.4 Hit verification 
Selected number of single colonies from the last round positive selection were screened by 
replication onto LB agar plates with varied concentration of chloramphenicol (34, 50, 75, 100, 150, 
or 250 μg/mL) in the presence or absence of the appropriate unAA. Only the clones that grew in 
the presence of unAA but did not grew in the absence of unAA were selected for further evaluation. 
5.4.5 Fluorescence analysis of bacterial culture 
E. coli GeneHogs harboring plasmids pBK-MjTyrRS variant and pLei-GFPuv-Asn149UAG90 
was cultured in 5 mL LB media containing kanamycin and chloramphenicol at 37 °C. The 
expression of GFPuv was induced at the OD600 of 0.6 by additions of IPTG (0.1 mM) in with or 
without unAA.  Following cultivation at 37 °C for additional 16 h, 1 mL of cell culture were 
collected, washed, and resuspended in 1 mL of potassium phosphate buffer (50 mM, pH 7.4). The 
processed cells were directly used for fluorescence and cell density measurement using Synergy 
H1 Hybrid plate reader (Bio-Teck Instruments). The fluorescence of GFPuv was monitored at λEx 
=390 nm and λEm =510 nm. The cell density was estimated by absorbance at 600 nm. The 
fluorescence intensity was normalized to cell density for comparison of different samples. 
Reported data was the average of two or more measurements with standard deviations. 
5.4.6 Protein expression and purification 
Similar cell cultivation procedure for fluorescence analysis was applied to preparing 50 mL 
of E. coli culture for protein purification. Cells were collected by centrifugation at 5,000g and 4 °C 
for 15 min. Harvested cells were resuspended in lysis buffer containing potassium phosphate (20 
mM, pH 7.4), NaCl (300 mM), and imidazole (10 mM). Cells were subsequently lysed by 
sonication. Cell debris were removed by centrifugation at 21,000g and 4 °C for 30 min. The cell-
free lysate was applied to Ni Sepharose 6 Fast Flow resin (GE Healthcare). Protein was purified 
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